Role of 3’UTR Elements in the Regulation of the Cyclin D1 Proto-oncogene by Deshpande, Anagha
 
 
From the Department of Medicine III, 
University of Munich Hospital Grosshadern 
Ludwig-Maximilians-University, Munich and 
The Helmholtz Centre Munich 
German Research Centre for Environmental Health 
Clinical Cooperative Group ‘’Leukemia’’ 
 
Chair: Prof. Dr. med. Wolfgang Hiddemann 
 
 
 
 
 
Role of 3’UTR Elements in the Regulation of the Cyclin D1  
Proto-oncogene 
 
 
 
 
 
Thesis Submitted for a Doctoral degree in Human Biology 
 at the Faculty of Medicine Ludwig-Maximilians-University,  
Munich, Germany 
 
 
 
 
Submitted by 
Anagha Deshpande 
 
 
From 
Thane, India 
 
2009 
 
 
Aus der Medizinischen Klinik und Poliklinik III am Klinikum 
Großhadern der Ludwig-Maximilians-Universität München 
Und dem Helmholtz Zentrum München, 
Deutsches Forschungszentrum für Umwelt und Gesundheit, 
Klinische Kooperations Gruppe Leukämie 
 
 
Direktor: Prof. Dr. med. Wolfgang Hiddemann 
 
 
 
 
 
Die Rolle von 3’UTR Elementen in der Regulation des Cyclin D1 
Proto-Onkogens 
 
 
 
 
 
Dissertation zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der Ludwig-Maximilians- 
Universität  zu München, Germany 
 
 
 
 
Vorgelegt von  
Anagha Deshpande 
 
 
Aus 
Thane, Indien 
 
2009 
 
 
 
 
With Permission from the Faculty of Medicine 
University of Munich 
  
 
 
 Supervisor/Examiner:  Prof. Dr. med. Martin Dreyling 
 
    
 Co-examiners:   Priv. Doz. Dr. Fuat Oduncu, M.A., E.M.B.
      Prof. Dr. Karl Sotlar    
  
 
 Dean:  Prof. Dr. med. Dr.h.c. Maximilian Reiser, FACR, FRCR 
  
 Date of Oral Exam:                 15.07.2009   
 
 
 
 
 
Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
  
 
 
 Berichterstatter:   Prof. Dr. med. Martin Dreyling 
    
 Mitberichterstatter:  Priv. Doz. Dr. Fuat Oduncu, M.A. , E.M.B.
      Prof. Dr. Karl Sotlar   
        
 
 
 Dekan: Prof. Dr. med. Dr.h.c. Maximilian Reiser, FACR, FRCR 
 
 Tag der Mündlichen Prüfung:  15.07.2009   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To 
 
Aai and Baba   
who have continuously showered me with love 
 and affection…
 
                                                                                                A  b  b  r  e  v  i  a  t  i  o  n  s 
 
 
Abbreviations 
 
               Ago Argonaut 
ALCL Anaplastic large cell lymphoma 
AREs AU-rich elements 
ATM ataxia talengiectasia mutated 
AUBP ARE binding protein 
B-ALL B acute lymphoid leukemia 
CCND1 Cyclin D1 
CDK Cyclin dependent kinase 
CLL Chronic lymphocytic leukemia 
del Deletion 
Fw Forward 
GFP Green fluorescent protein 
IL Interleukin 
ins Insertion 
MCL Mantle cell lymphoma 
miRNAs MicroRNAs 
mRNA Messenger RNA 
NFκB Nuclear factor κB 
NHL non-Hodgkin's lymphoma 
nt Nucleotide 
PCR Polymerase chain reaction 
PTEN phosphotase and tensin homologue 
Rb Retinoblastoma 
Rev Reverse 
RISC RNA-induced silencing complex 
T-ALL T acute lymphoid leukemia 
TBP TATA-box binding protein 
UTR Untranslated region 
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Introduction 
 
1.1 Oncogenesis: 
 Cancer is now widely viewed as a multistep process involving the progressive 
accumulation of multiple mutations leading to the activation of oncogenes and the inactivation of 
tumor suppressor genes. Often, the deregulation of distinct pathways and processes by these 
accumulating mutations is a necessary prerequisite for tumor formation. Recent studies involving 
genetic and molecular techniques have provided tremendous insights into the biology of 
lymphoma. These studies have led to the understanding that lymphoma is composed of several 
distinct subsets with characteristic genetic, cytogenetic, biochemical and morphological features. 
The recent focus in lymphoma research has been the identification and characterization of specific 
molecular alterations and the determination of their correlation with disease progression and 
treatment outcome. Genetic changes in lymphoma include microscopically detectable 
chromosomal alterations, sub-microscopic alterations such as small deletions and inversions and 
even more inconspicuous mutations at the genomic level.  
 Since the discovery of the Philadelphia chromosome, recurrent chromosomal 
abnormalities such as translocations, deletions, inversions and duplications associated with 
several types of leukemia, lymphoma as well as certain types of epithelial tumors have been 
identified (Look, 1997; Rabbitts, 1994; Rowley, 1998).  These chromosomal abnormalities are 
often somatic mutations acquired by a clonally expanded malignant population. As is the case 
with CML, certain chromosomal abnormalities can be associated with specific types of disease 
and the characterization of these abnormalities can be used for diagnosis as well as for the 
determination of disease prognosis. Moreover, treatment regimens can be optimized to suit 
discrete sub-groups divided according to these abnormalities.  
Chromosomal abnormalities such as translocations cause oncogenic activation through 
one of two mechanisms. The first mechanism involves a fusion of the coding regions of two 
proto-oncogenes, which in turn results in a chimeric or fusion protein with altered functions. As 
an example, the t(15;17) translocation fuses the retinoic acid receptor α (RAR α) to the myeloid 
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transcription factor PML, forming a fusion product in acute promyelocytic leukaemia (APL). 
(Kakizuka et al., 1991). The second mechanism involves the juxtaposition of proto-oncogenes to 
one of the regulatory regions of immunoglobulin genes or T-cell receptor loci (Boehm and 
Rabbitts, 1989; Cleary, 1991; Korsmeyer, 1992). These latter type of rearrangements are mostly 
observed in lymphoid malignancies such a B and T acute lymphoid leukemia (B-ALL and T-
ALL) and different types of lymphomas. Examples of this type include the t(8;14) in Burkitt 
lymphoma/leukemia and the t(14;18) in follicular lymphoma. The former type of chromosomal 
translocations occur in some types of non-Hodgkin lymphoma, such as the t(2;5) in anaplastic 
large cell lymphoma (ALCL), but are best known in acute and chronic myeloid leukemias.  
In Mantle cell lymphoma (MCL), which will be described in more detail in the following 
section, the cyclin D1 gene which is normally not expressed in normal B cells, is juxtaposed to 
the immunoglobulin heavy chain enhancer (IgH),by the t(11;14) translocation leading to its 
ectopic, constitutive overexpression .   
 
1.2 Mantle cell lymphoma: 
Mantle cell lymphoma was first described as centrocytic lymphoma, an independent 
subtype of non-Hodgkin’s lymphoma (NHL), according to the Kiel classification in 1974. With 
the introduction of the general WHO tumour classification in the year 2001 this subtype was 
designated as mantle cell lymphoma.  MCL is an aggressive form of lymphoma that accounts for 
about 5 to 10% of NHL. It has a poor prognosis with the average survival rate of 3-4 years. As 
discussed above, the t(11;14)(q13;q32) translocation is the hallmark of the disease which 
juxtaposes the cyclin D1 gene at 11q13 to the IgH at 14q32 leading to overexpression of cyclin 
D1 (Rimokh et al., 1994b). 
1.2.1 Clinical characteristics of mantle cell lymphoma:  
 MCL is a well defined lymphoid neoplasm that is characterised by the proliferation of 
mature, naive B cells. These cells possess a tendency to disseminate throughout the body 
infiltrating the bone marrow, peripheral blood and extranodal sites. This tumor is prevalent in 
males with advanced age of around 60 years. Despite new therapies being developed, MCL 
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patients show a median survival of 3-5 years and frequent relapses. MCL has a spectrum of 
morphologically different cytological variants such as classical MCL, blastoid MCL and 
pleomorphic MCL as shown in Fig.1.2a 
 
 
Fig.1.2a Histological variants of MCL (figure from Jares P., 2007) Different variants of MCL are depicted in 
the figure: classical MCL have small to medium sized B cells with irregular nuclei and inconspicuous nucleoli 
whereas blastoid variants show rounded nuclei, finely dispersed chromatin. The pleomorphic and blastoid 
variants have higher proliferation rates, complex karyotype and aggressive clinical behaviour. 
 
1.2.2 Treatment strategies for mantle cell lymphoma: 
Since various important signalling pathways are activated in MCL cells leading to 
enhanced cell proliferation, the treatment of MCL patients remains a challenge. Conventional 
therapy includes chemotherapeutic regimens based on the CHOP regimen that includes 
cyclophosphamide, hydroxydoxorubicin, oncovin (vincristine) and prednisone or HyperCVAD 
(an intense standard chemotherapeutic regimen based on the CHOP combination but also 
including high doses of methotrexate and cytarabine) in the initial phase of the disease. 
HyperCVAD is also given in combination with rituximab (anti-CD20 monoclonal antibody) for 
initial treatment (Jares et al., 2007; Witzig et al., 2005). However, despite the benefits of this 
multimodal approach, most patients relapse even after high-dose therapy. It has been stated that 
the only curative approach is allogeneic stem cell transplantation, which may be adapted to the 
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elderly MCL patient cohort by modified dose-reduced conditioning regimens (Hiddemann and 
Dreyling, 2003).  
In past few years new strategies are being developed that target the crucial pathways and 
may change the management and outcome of MCL patients. As the PI-3K/mTOR pathway seems 
to be involved in MCL, the mTOR inhibitor Ramapamycin and its derivative RAD001 were 
tested in MCL cell lines. These molecules have been shown to induce cell cycle arrest without 
causing apoptosis. As a single agent, RAD001 inhibited proliferation in MCL cell lines. 
Furthermore, RAD001 showed predominantly synergistic cytotoxicity in combination with 
several secondary agents, including doxorubicin, vincristine or rituximab (components of the 
standard MCL regimen), as well as paclitaxel, vorinostat and bortezomib (Haritunians et al., 
2007). These results suggest the potential use of these cytostatic drugs alone or in combination in 
the treatment of MCL. The other cell cycle inhibitor molecules include the CDK inhibitor 
Flavopiridol which is being explored in relapsed MCL patients. 
The ubiquitin-proteasome system has become a promising novel molecular target in 
cancer due to its critical role in cellular protein degradation, its interaction with cell cycle and 
apoptosis regulation and its unique mechanism of action. Bortezomib as first-in-class proteasome 
inhibitor has proven to be highly effective in some hematological malignancies including 
relapsed mantle cell lymphoma (Kane et al., 2007). It reversibly inhibits the 26S proteasome, a 
large protein complex that degrades many of the intracellular proteins. Inhibition of the 
proteasome prevents this targeted proteolysis of pro-apoptotic proteins which may result in 
alteration of many signalling cascades in cells. In addition to all the therapies targeting different 
pathways, there are certain therapies used in clinical practice which induce apoptosis in tumor 
cells. Apoptosis depends on the activation of caspases by either intrinsic or extrinsic pathways 
that require activation of the tumor necrosis factor (TNF) family of cell death receptors by their 
related ligands and TNF-related apoptosis inducing ligand (TRAIL). TRAIL was reported to 
induce apoptosis selectively in neoplastic cells through DR4 receptors (MacFarlane et al., 2005). 
Thus, agents such as TRAIL and anti-CD4 antibodies are being investigated in the treatment of 
MCL.  
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1.2.3 Cellular biology of MCL: 
 The ectopic expression of cyclin D1 in B lymphocytes is considered to be the primary 
event in the pathogenesis of MCL, probably facilitating the deregulation of cell cycle at G1-S 
transition. Analysis of the breakpoint regions in the two chromosomes has suggested that this 
translocation occurs in the bone marrow in an early B cell at the pre-B stage of differentiation 
when the cell is initiating the Ig gene rearrangement with the recombination of the V(D)J 
segments (Jares et al., 2007). The immunophenotype of MCL cells reflects a mature B-cell 
arrangement (CD45+, CD19+, CD20+, CD22+, CD24+, CD 79a+). MCL cells are CD5+and CD43+ 
but CD23- as well as CD10-. These neoplastic cells of MCL tend to colonize the mantle zone of 
the lymphoid follicles, hence the term mantle cell lymphoma was designated for this tumour. 
Although the t(11;14) translocation occurs in an immature B cell in the bone marrow, the 
selective oncogenic advantage of this chromosomal aberration fully develops when these cells 
attain the differentiation phase of a mature naive pre-germinal centre B cell (Banks et al., 1992). 
According to the origin from pre-germinal centre cells, most of the MCL samples have no or very 
few somatic mutations in V-gene sequences of Ig (VH) genes.  However, 15-40% of MCLs do 
carry somatic hyper-mutations which indicate that some tumors originate in cells that have 
undergone the influence of the mutational machinery of the follicular germinal centre. 
1.2.4 Molecular biology of MCL: 
Ectopic and deregulated expression of cyclin D1 is believed to be one of the causes of 
oncogenesis in MCL. Cyclin D1 in combination with cyclin dependent kinases (CDK) 4 and 6 
(CDK 4 and CDK 6) regulates the cell cycle transition between the G1 to the S phase. Cyclin D1 
binds to the CDK 4/6, cyclin D1-CDK 4/6 complexes which then phosphorylate the 
retinoblastoma (Rb) protein, leading to the inactivation of its suppressive effect on cell cycle 
progression. The hyperphosphorylated Rb protein in turn releases the E2F transcription factors 
which force the cell to enter the S phase and eventually commit itself to the cell cycle. The 
hyperphosphorylation of Rb in MCL cases demonstrates the role of cyclin D1 in these tumors by 
overcoming the cell cycle suppressive effect of Rb (Jares et al., 1996). However, recently 
identified intragenic deletions of Rb leading to complete lack of protein expression in some cases 
of MCL suggest an oncogenic role of cyclin D1 independent of Rb in these tumors (Pinyol et al., 
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2007). Overexpressed cyclin D1 sequesters free p27kip1 into cyclin D1-CDK4/6 complexes which 
would decrease the active form of p27kip1 in the cell, making it incapable of inducing G1 cell 
cycle arrest. This inactive form of p27kip1 might be reducing inhibition on CDK2-cyclin E, 
facilitating entry into S phase thus potentiating lymphomagenesis (Quintanilla-Martinez et al., 
2003). 
Apart from cyclin D1 overexpression, there are other dysregulated pathways which 
contribute to pathogenesis of MCL. Cytogenetic analysis has demonstrated that MCL is one of 
the lymphoid neoplasms with the highest number of chromosomal aberrations that include losses, 
gains and amplification of genes involved in tumor progression (Salaverria et al., 2006). Clinical 
observations also supported the need for additional oncogenic events in MCL. The search for 
potential target genes altered in MCL has identified that most of them are involved in two 
common pathogenetic pathways, cell cycle and the DNA damage response (Fig.1.2b). 
 
Fig.1.2b Cell cycle and DNA damage response pathway dysregulation in MCL. (Figure from Jares P. et al., 
2007) This figure depicts the involvement of different genes in deregulation of the cell cycle and DNA damage 
response pathway, cell cycle deregulation is indicated on the left hand side of the figure whereas the right 
hand side shows the factors involved in the DNA damage response pathway.  
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Cell cycle deregulation: The two main regulatory pathways involved in the control of 
cell cycle and senescence, namely the INK4a-CDK4-RB1 and the ARF-MDM2-p53 pathways 
are dysregulated in highly proliferative MCLs. Inactivation of CDKN2A is observed in a large 
number of cases. The locus on chromosome 9p21 which is deleted in MCLs, encodes two key 
regulatory elements, CDK inhibitor INK4a and the p53 regulator ARF. As the name suggests 
INK4a inhibits CDK4 and 6 and maintains Rb in its active form. Thus, the genomic deletion of 
9p21 and cyclin D1 overexpression, together lead to the hyperphosphorylation of Rb and cell 
cycle progression. The prime function of ARF (located at 9p21) is to protect p53 from 
degradation by MDM2 mediated proteasome inhibition (Rosenwald et al., 2003). (Fig.1.2b). p53 
inactivation is therefore caused by high levels of MDM2 and deletion of 9p21 locus in some of 
MCL cases (Hernandez et al., 2005). Tumors with wild type CDKN2A show mutated p53 and 
CDK4 amplification which suggests that the simultaneous inactivation of both pathways, INK4a-
CDK4-RB1 and ARF-MDM2-p53 probably provides a selective proliferative advantage to the 
cells. 
DNA damage response pathway alterations: The ataxia talengiectasia mutated (ATM) 
gene encodes a serine-threonine kinase belonging to the phosphotidylinositol-3 kinase (PI-3K) 
family. This enzyme is involved in DNA damage response signalling pathways. Different studies 
have now identified a number of targets of the ATM gene including p53. In response to various 
DNA damaging agents, ATM phosphorylates p53 leading to its stabilization and cell cycle arrest 
and apoptosis. This ATM gene is mutated in different lymphoproliferative diseases including 
MCL (Camacho et al., 2002). These mutations mainly affect the PI-3K domain or lead to 
truncated ATM proteins that are rapidly degraded. Due to ATM mutation and p53 inactivation, 
there is loss of apoptosis which is one of the mechanisms of MCL pathogenesis. 
Cell survival pathway dysregulation: In addition to the alterations in cell cycle control 
and DNA damage response pathways; MCL may also have activated cell survival mechanisms. 
Recent gene profiling studies showed that many individual genes involved in signalling pathways 
that affect cellular proliferation are either overexpressed or underexpressed in MCL cases. Many 
of these overexpressed genes are the members of PI-3K Akt signalling pathway including 
PIK3CA, Akt-1, PDK-1, and PPP1R2. This signaling pathway is known to be involved in the 
transduction of extracellular stimuli that regulate fundamental cellular processes including cell-
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cycle progression, proliferation and cell growth, apoptosis, and survival (Rudelius et al., 2006). 
This pathway is reported to be constitutively active in a subset of MCL that includes the 
aggressive blastoid variants and is associated with the loss of its negative regulator, phosphatase 
and tensin homologue (PTEN). Further, constitutive activation of nuclear factor κB (NFκB), that 
regulates genes involved in both cell survival as well as apoptotic signalling pathways has also 
been reported in MCL cell lines and primary tumours.  
Thus, the activation of these two major pathways leads to increased cell proliferation, 
survival and inhibition of apoptosis in MCL. 
 
1.3 Cyclin D 1: 
The cell cycle clock coordinates the progression of eukaryotic cells through their growth 
and division cycles. Its importance is being increasingly appreciated as it is the master controller 
of a cell’s decision to continue proliferating or to withdraw from the cycle and enter a state of 
quiescence. In 1998, Robert Weinberg’s group (Jacks and Weinberg, 1998) pointed to a wider 
role for components of the cell cycle machinery. The core components of it include cyclins and 
cyclin dependent kinases along with cyclin dependent kinase inhibitors, Rb protein (Jacks and 
Weinberg, 1998). As the name cyclins suggests, the amounts of these proteins oscillate during 
different phases of cell cycle. There are three types of cyclins in mammalian cells, S phase 
cyclins, G2-M cyclins and G1 cyclins. G1 cyclins include D and E type cyclins. D type cyclins 
are cyclin D1, D2 and D3. The cyclin D1 protein plays an important role in the G1-S transition of 
a cell.  
The human cyclin D1 gene was initially cloned as a breakpoint rearrangement in 
parathyroid adenoma. Motokura and colleagues found the D11S287E transcript that is always 
overexpressed in parathyroid adenomas, and named it PRAD1 (Motokura et al., 1991). Other 
researchers later identified it as cyclin D1 (CCND1). Cyclin D1 encodes two distinct mRNA 
transcripts, a 1.7kb transcript, (transcript b) and a longer 4.4kb (transcript a) (Betticher et al., 
1995). Sequencing of the cyclin D1 mRNA from these two transcripts shows no differences in 
the coding region but a single base pair A/G polymorphism at position nt870. Earlier it was 
thought that this polymorphism plays a role in alternative splicing by favoring the expression of 
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one of the two isoforms. It was shown that in case of the ‘G’ allele, splicing from exon 4 to exon 
5 (transcript a) is favoured and the ‘A’ allele is more likely not to splice at this junction leaving 
the coding sequence reading into intron 4. The protein from transcript b (isoform b) differs in the 
carboxy-terminus from isoform a, which bears the PEST destruction box. Phosphorylation of 
cyclin D1 takes place at a conserved carboxy terminal residue Thr 286, which exports it out of 
the nucleus at the G1-S boundary. Since isoform b lacks this carboxy-terminus, it has been shown 
to be an isoform that always remains in the nucleus during the cell cycle unlike the canonical 
isoform a (Betticher et al., 1995).  
1.3.1 Cyclin D1 as cell cycle regulator: 
 As mentioned above, cyclin D1 has been reported to be one of the key regulators of cell 
cycle machinery especially in G1 to S transition. It serves as a key sensor and integrator of 
extracellular signals of cells in early to mid-G1 phase mediating its function through binding both 
the CDKs and histone acetylases and deacetylases to modulate local chromatin structure of genes 
that are involved in cell proliferation and differentiation (Huang et al., 1998). Cyclin D1 encodes 
the regulatory subunit of the serine-threonin kinases (CDKs), CDK4 and CDK6. The 
identification of the catalytic partners of the D-type cyclins established these proteins as bona 
fide cyclins. Cyclin D1 binds to CDK4/6 to form cyclin/CDK complexes. These complexes 
further act on Rb and cause its phosphorylation. Rb acts as a gatekeeper at the G1-S transition by 
binding to the E2F transcription factors. Phosphorylation of Rb at the C terminus due to 
cyclin/CDK complexes inhibits its function of restricting the entry of a cell into the S phase. This 
promotes the release of E2F transcription factors from Rb-E2F complexes. This in turn leads to 
transcriptional induction of genes necessary for progression from G1 to S phase; most notably 
cyclin E. Complete inactivation of Rb is mediated by the cyclin E-CDK2 holoenzyme, whose 
activation is facilitated by non-catalytic function of the cyclin D-CDK complex involving the 
titration of CDK inhibitors, p21 and p27. Thus, cell cycle regulation is a CDK dependent function 
of cyclin D1. 
1.3.2 CDK independent functions of cyclin D1: 
In addition to a well established role in controlling the progression of cell through G1-S 
phase in cell cycle in concert with CDKs, CKD independent roles for cyclin D1 have also been 
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documented. Cyclin D1 has been shown to affect the activity of several transcription factors. It 
forms a physiological association with 30 different transcription factors or coregulators including 
androgen receptor (AR), estrogen receptor (ER) α, thyroid hormone receptor and STAT3 (signal 
transducer and activator of transcription) (Bienvenu et al., 2001; Coqueret, 2002; Knudsen et al., 
1999; Neuman et al., 1997).  It has been reported that cyclin D1 associates with the TATA-box 
binding protein associated factor(II)250 and suppresses pRb mediated inhibition of  TATA-box 
binding protein associated factor(II)250 kinase activity (Siegert et al., 2000) . In addition to in-
vitro analysis of cyclin D1 functions, mouse models have also been studied to demonstrate the 
physiological role for cyclin D1. Mice deficient in cyclin D1 are small and display retinal 
hypoplasia and defects in lobulo-alveolar development during pregnancy. Creating mice deficient 
both in cyclin D1 and p27 rescued the defects that characterize cyclin D1 deficient mice which 
prove the aforementioned physiological role for cyclin D1 (Ewen and Lamb, 2004; Fantl et al., 
1995). 
1.3.3 Cyclin D1 as proto-oncogene:  
In the mammalian cell cycle, there is a restriction point at the entry of S phase. This point was 
defined for the first time, as the time point at which the cell loses reliance upon external signals 
necessary for continued cell cycle progression. The restriction point control is proposed to permit 
normal cells to retain viability by a shift to a minimal metabolism upon differentiation in-vivo 
and in-vitro when conditions are suboptimal for growth. Malignant cells are believed to have lost 
their restriction point control and this loss is described as the consequence of overexpressed 
cyclin D1 (Pardee, 1974).  Uncontrolled cell proliferation is the hallmark of cancer and tumor 
cells typically acquire mutations of genes that directly regulate their cell cycles. It has been 
proposed that oncogenic processes exert their greatest effect by targeting regulators of G1 phase 
progression in particular (Sherr, 1996). The pRb and p53 pathways have been observed to be 
dysregulated in most cancer types and cyclin D1 is targeted by both of these pathways. Its 
overexpression in several different malignancies, including breast cancer, parathyroid cancer, 
colon cancer and mantle cell lymphoma is believed to lead to increased cell proliferation and 
tumor formation.  
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Deregulation of cyclin D1 in cancer 
 Amplification, mutation or overexpression may be the cause of deregulated cyclin D1 in 
various neoplasms. Callender et al. reported the amplification of cyclin D1 gene in around 34% 
of head and neck squamous carcinoma samples (Callender et al., 1994). Amplification was more 
noted in high grade, high stage, and aneuploid tumors showing a highly statistical correlation 
between PRAD-1 amplification and proliferative activity. This indicated that cyclin D1 
amplification is a late event in the tumorigenesis of head and neck carcinoma and is often 
associated with a subset of aggressive tumors and highly proliferative neoplasms. Amplification 
of the cyclin D1 gene was also observed in breast cancer cell lines and its overexpression was 
observed in 45% of primary tumors (Buckley et al., 1993). Similarly, cyclin D1 amplification 
was observed in neuroblastoma tumors and cell lines (Molenaar et al., 2003). In some tumors, the 
degree of overexpression of this proto-oncogene is said to be higher than what can be attributed 
to cyclin D1 gene amplification. Cyclin D1 amplification was found in 15% of primary human 
breast cancers (Hosokawa and Arnold, 1998) and overexpression in 30-50% of breast cancers, 
suggesting that mechanisms in addition to DNA amplification may lead to deregulated expression 
of this gene in breast cancer.  
 As mentioned previously, proto-oncogene overexpression can result from genomic 
translocations involving the oncogene. The cyclin D1 gene was discovered as a transcript on 
chromosome 11q13 (initially termed D11S287E) which is clonally rearranged with the 
parathyroid hormone locus in a subset of benign parathyroid tumors. In parathyroid adenomas 
and carcinomas, the cyclin D1 protein is overexpressed as a result of its clonal rearrangement, 
leading to tumorigenesis (Rimokh et al., 1994b). In MCL, the t(11;14)(q13;q32) translocation 
juxtaposes the cyclin D1 gene to the IgH enhancer which leads to overexpression of the protein 
contributing to tumor formation. Recently, other mechanisms including mutations in cyclin D1 at 
the genomic level have been reported in addition to the translocation which might play a role in 
overexpression of cyclin D1 in MCL. 
Even though mutations that alter the coding sequence of this gene have rarely been 
reported in cancer, there are several reports that point to somatic mutations in the 3’ untranslated 
region (UTR) of the cyclin D1 mRNA. A truncation of the cyclin D1 gene in its 3’UTR has been 
reported in a human breast cancer cell line associated with overexpression of the protein. In 
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mantle cell lymphoma patients, a truncation in 3’UTR of cyclin D1 gene was observed and it was 
proposed that the truncation of the 3’UTR eliminates cis-acting elements such as AU rich 
sequences (AREs) leading to increased mRNA stability and hence increase in cyclin D1 protein 
expression (Rimokh et al., 1994a). In addition to these mutations, the cyclin D1 isoform b which 
harbors a shorter 3’UTR has been reported to be the cause of tumorigenesis in cancers such as 
esophageal carcinomas (Lu et al., 2003). People have suggested that the isoform b being nuclear 
during the cell cycle binds to CDK4/6 and constitutively inactivates the pRb pathway leading to 
increased cell proliferation and tumorigenesis in different cancers including MCL. However, it 
has recently been proved that both the isoforms exist in all tumor samples as well as in their 
normal counterparts and the ratio of mRNA expression of isoforms a and b does not play any role 
in cancer progression (Krieger et al., 2006; Wiestner et al., 2007). The cyclin D1 isoform b, 
although present in the nucleus, can not inactivate the pRb pathway, thereby causing no changes 
in cell cycle progression. Increased stability of isoform b was also predicted to be the cause of 
cyclin D1 mediated tumorigenesis but it was recently shown to have comparable stability as 
compared to the a isoform (Holley et al., 2005; Leveque et al., 2007; Solomon et al., 2003). In 
fact the shorter isoforms of the cyclin D1 gene in MCL result from genomic deletions of the 
3’UTR or from point mutations that prematurely truncate the cyclin D1 3’UTR in a majority of 
MCL patients. These shorter mRNAs are cyclin D1 a isoforms, not alternatively spliced cyclin 
D1b mRNA isoforms (Wiestner et al., 2007). Premature polyadenylation due to a 3’UTR 
mutation is also observed in the Z-138 MCL cell line expressing both truncated and full-length 
cyclin D1a mRNAs. Mutations in the 3’UTR create the premature polyadenylation signals within 
300 bp from the stop codon. A 3 bp ‘TCA’ deletion at 309-311 position after the stop codon of 
cyclin D1 is found in one MCL case whereas a single bp ‘A’ insertion between nucleotides 
number 308 and 309 in another. Both types of mutations create a polyadenylation signal at an 
identical site, 304 bp 3’ of the stop codon. Interestingly, shorter mRNAs of cyclin D1 are more 
stable than full-length mRNAs since they lack mRNA destabilizing elements as discussed by 
Rimokh et al. These data thus suggest that genetic events causing mutations or deletion in the 
3’UTR of the cyclin D1 gene enhance the effect of the t(11;14) translocation by generating higher 
levels of cyclin D1 mRNAs and protein, leading to an increased cell cycle progression through 
the G1-S phase. These observations made in MCL and other tumours point to the role of 3’UTR 
of cyclin D1 gene in malignant transformation. Detailed studies on the contribution of this region 
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to cyclin D1 expression and to malignant transformation are therefore necessary and are the focus 
of this dissertation. 
 
1.4 3’UTR mediated gene regulation: 
Eukaryotic gene expression is controlled at the levels of transcriptional and translational 
initiation and elongation at both these levels regulates gene expression. After transcription, the 
messenger RNA (mRNA) is either translated into protein or degraded, depending upon its 
function in the cell. mRNAs for genes such as c-fos, that is involved in the response of cells to 
the external environment, are degraded rapidly in the cytoplasm with a half life of 8-30 minutes 
whereas β-globin mRNA in erythroid cells is quite stable with a half life of greater than 24 hours 
(Atwater et al., 1990). Cyclins, genes involved in cell cycle regulation, undergo rapid turnover 
with less mRNA stability. The stability of mRNA depends on different regions like the 3’and 
5’UTRs containing cis-acting elements and trans-regulating factors binding directly or indirectly 
to these cis-acting elements. The formation of mRNA-protein complexes followed by a series of 
re-modelling events, influence the translation and decay of mRNAs.  
The 3’UTR of mRNAs is proposed to be one of the most important factors regulating 
mRNA stability. The presence of numerous cis-acting elements in this region and the binding of 
proteins, make it an important regulatory unit. It has been shown that alterations in the 3’UTR of 
many transiently expressed genes leads to enhanced stability of their mRNAs leading to 
overexpression and oncogenesis (Jones and Cole, 1987; Mayr et al., 2007) indicating its role in 
gene expression. There are several recognised motifs in 3’UTRs that could be crucial for the 
regulation of mRNAs. Of these, AU-rich elements (AREs) have been characterised in some 
detail. Moreover, in the last few years, there is mounting evidence that the 3’UTR of several 
mRNAs harbour binding sites for microRNAs, a class of small noncoding RNAs that regulate 
gene expression. Since this thesis describes the regulation of the cyclin D1 gene by these two 
types of motifs in the 3’UTR, AREs and microRNAs will be discussed in the following sections.  
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1.4.1 AU rich elements in the 3’UTR: 
Adenylate/uridylate rich elements or AREs are the highly conserved elements found in the 
3’UTRs of many mRNAs that code for proto-oncogenes, cytokines and nuclear transcription 
factors (Chen and Shyu, 1995) and function as elements that are important for mRNA stability. 
They are the most common and well studied cis-acting elements in the 3’UTR. 10% of human 
mRNAs are reported to contain AREs in their 3’UTRs. The first direct evidence that the ARE can 
function as a potent mRNA destabilizing element came from a study by Shaw and Kamen in 
1986. The stability of β-globin mRNA was reduced considerably by inserting a conserved region 
of 51 nucleotides containing AUUUA motifs from the 3’UTR of human granulocyte-macrophage 
colony-stimulating factor (GM-CSF) into its 3’UTR (Shaw and Kamen, 1986). Later, the mRNA 
degradation of c-fos, c-myc, β-interferon and many more genes was also shown to be the effect of 
AREs in their respective 3’UTRs (Chen et al., 1994; Chen and Shyu, 1994; Jones and Cole, 1987; 
Peppel et al., 1991). 
AREs are proposed to be of three types, class I and II AREs containing various repeats of 
AUUUA signature motifs and class III lacking this pentamer (Xu et al., 1997). There appears to 
be a sequence hierarchy by which the three classes of AREs are composed from several key 
sequence features. AREs classified as class I are found in early-response gene mRNAs that 
encode various transcription factors and mRNAs for some cytokines like IL-4, IL-6. They contain 
one to three copies of AUUUA motifs coupled with nearby U-rich sequences. Each of these 
sequence features plays a distinct role and together they determine the destabilizing potency of 
the class I AREs (Chen et al., 1994).  Class II AREs possess multiple repeats of the AUUUA 
pentamer clustered together and the class III AREs contain only a couple of U stretches and a U-
rich domain. The class II AREs direct asynchronous cytoplasmic deadenylation which is 
consistent with a processive ribonucleolytic digestion of polyA tails whereas class I and AUUUA 
less class III AREs mediate synchronous polyA shortening followed by the decay of the mRNA.  
Existence of cross talk between the AREs and the 3’ end polyA tail dictates the rate and kinetics 
of cytoplasmic deadenylation and thereby the fate of the corresponding mRNA (Xu et al., 1997). 
The length of AREs, especially the number of overlapping pentamers may also contribute to 
mRNA half life (Akashi et al., 1994). When ARE mRNAs in endotoxin stimulated monocyctes  
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were clustered into class I and class II categories by bioinformatic analysis, the mRNAs having 
class II AREs showed shorter half lives than those of class I (Frevel et al., 2003; Khabar, 2005).  
Mechanisms of ARE mediated mRNA stability: 
 As mentioned above, AREs play a major role in mRNA stability by either degradation or 
enhanced translation. One of the mechanisms of ARE mediated mRNA degradation or 
stabilization includes binding of ARE binding proteins (AUBP) to ARE mRNAs. HuR and AUF1 
are among the AUBPs that have been discovered. HuR, a member of the ELAV/Hu family 
consists of the closely related proteins,HuB, HuC, and HuD (Ma et al., 1996). It has been shown 
to bind and stabilize many ARE mRNAs in several different cell systems. It is mainly located in 
the nucleus but shuttles between cytoplasm and nucleus depending on the stabilization of mRNA 
transcripts. Unlike HuR, AUF1 is one of the mRNA destabilizing AUBPs. The AUF1 gene is 
expressed as four isoforms designated by their molecular weights, p37, p40, p42 and p45 which 
are generated by alternative splicing of a pre-mRNA transcript (Wagner et al., 1998). All four 
isoforms are predominantly nuclear but their transport between nucleus and cytoplasm is 
dependent on external stimuli (David et al., 2007; Sarkar et al., 2003; Suzuki et al., 2005). A 
structurally different class of proteins, the CCCH tandem zinc finger family also includes some 
AUBPs such as tristetraproline (TTP). It has been reported to bind to and stabilize several 
mRNAs such as IL-3, TNF-α and GM-CSF (Blackshear, 2002; Carballo et al., 2000; Stoecklin et 
al., 2000). The AUBPs may not degrade or stabilize the mRNAs directly but may be through 
complex protein-protein interactions. They may also regulate the mRNA stability through their 
interaction with the exosome, a multiprotein complex that has 3’-5’ exonuclease activity (Chen et 
al., 2001). In addition to these AUBPs, the ubiquitin-proteasome pathway has also been shown to 
participate in ARE mediated mRNA decay. The link between the proteasome pathway and rapid 
degradation of cytokine mRNAs has been reported suggesting a complex interplay between 
proteasomes, polyA binding protein (PABP), heat shock proteins and translational control in 
ARE-mRNA decay (Laroia et al., 1999).  
 Some signalling pathways have also been shown to be involved in ARE mediated mRNA 
stability. The p38 mitogen-activated protein kinase (MAPK) pathway has been reported to play a 
role in degradation of different mRNAs such as IL-3, IL-6, TNF-α and VEGF (Pages et al., 2000; 
Wang et al., 1999; Winzen et al., 1999). The AU rich 3’UTRs of IL-6 and TNF- α are 
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downstream of p38 MAP kinase-activated protein kinase (MAPKAP K2 or MK2) and make it an 
essential component of their ARE dependent mRNA stabilization. It is proposed that the MK2 
phosphorylates an uncharacterised downstream target that directly or indirectly binds to AREs 
leading to ARE mediated mRNA translational control.  
Thus, by different mechanisms, AREs play a role in 3’UTR mediated post transcriptional 
regulation of numerous genes. The deletion of these elements could contribute to pathogenesis in 
certain disorders including cancer. As an example, in systemic lupus erythematosus (SLE) T- 
cells, there is reduced expression of TCR ζ protein which is the result of alternatively spliced 
isoform of TCR ζ that undergoes a deletion within the 3’UTR. This deletion includes two repeats 
of the ARE pentamer (Chowdhury et al., 2006). The reduced protein expression is linked to the 
deletion of AREs in the 3’UTR that otherwise either stabilize the TCR ζ mRNA or increase its 
translation. In addition, the transforming ability of the oncogene c-fos was shown to correlate 
with the deletion of an ARE containing region from its 3’UTR. (Raymond et al., 1989). 
1.4.2 MicroRNAs (miRNAs): 
1.4.2.1 The discovery: 
In 1981 Chalfie M. et al. discovered the Caenorhabditis elegans lin-4 gene 
(Chalfie et al., 1981) which was found to play an important role in larval development since 
mutations in this gene caused heterochronic defects. Later in 1993, it was found that lin-4 does 
not encode a protein (Lee et al., 1993). Two small lin-4 transcripts of approximately 22nt and 
61nt were identified in C.elegans, the 61nt long transcript was predicted to form a hairpin 
secondary structure and is the precursor of the 22nt RNA. Lin-4 was found to contain sequences 
complementary to a repeated sequence element in the 3’UTR of lin-14 mRNA suggesting that 
lin-4 regulates the translation of lin-14 by antisense RNA-RNA interaction. Further it was 
reported that lin-28, a cold-shock protein that regulates the transition between larval stages 2 and 
3, also possesses the sequences complementary to the 22 nt transcript of lin-4 in its 3’UTR (Moss 
et al., 1997). Thus, the lin-4 gene was found to regulate the protein expression of the mRNAs, 
lin-14 and lin-28. Later Reinhart and colleagues discovered let-7, (Reinhart et al., 2000) and 
reported that the let-7 RNA regulates developmental stages in C.elegans. For some time lin-4 and 
let-7 were the only known naturally occurring small antisense RNAs in eucaryotes. Later 
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homologues of let-7 were found in D.melanogaster, animals and humans. Studies in plants and 
fungi uncovered the mechanisms by which these transgenes regulate homologous genes (Pal-
Bhadra et al., 1997). This mechanism was described as cosuppression or posttranscriptional gene 
silencing (PTGS). 
 PTGS was followed by the discovery of dsRNA which worked better than the antisense-
RNA mediated gene silencing. Hence, this finding was fundamental for the identification of 
dsRNA as the trigger for PTGS. Soon after, the term RNA interference (RNAi) was coined as 
one of the cellular mechanisms conserved among most eucaryotes. Further discoveries showed 
the connection between small regulatory RNAs and RNAi. It was shown that dsRNA is 
specifically processed to 21nt RNA in Drosophila embryonic extract. These RNAs were named 
as small interfering RNAs (siRNAs) (Elbashir et al., 2001) which guide the RNAi machinery to 
target mRNAs. The RNAi mechanism, specifically siRNAs seemed reminiscent of lin-4 and let-7 
RNAs, fostering the idea that these regulatory RNAs may be natural RNAi triggers (Chang and 
Mendell, 2007). Further the presence of let-7 was reported in human cell lines and other human 
and Drosophila RNAs with conserved stem-loop precursors were discovered which were 
collectively named as microRNAs (miRNAs). After the discovery of the first few hundred 
miRNAs by cloning, sufficient miRNA sequences were available to begin applying bioinformatic 
analyses to scan genomes for additional miRNA genes. Thus over the past few years, the field of 
miRNAs has been extensively explored since these small non-coding RNAs have been shown to 
fine tune the expression of several genes. 
1.4.2.2 Biogenesis of miRNAs:  
MiRNAs are 20-22nt long, transcribed from long autonomous transcription units. 
Some of the miRNAs that were found in close proximity to others were found to be clustered 
miRNAs 
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Fig.1.4.2a Biogenesis of microRNAs (figure from Slack F J., Nat.Rev.Cancer.,2006) This figure indicates the 
process of microRNA (miRNA) biogenesis in a cell. The blue boxes label the microRNA at different stages of 
biogenesis. In the nucleus, the miRNA gene is transcribed into a primary miRNA which is then acted upon by 
Drosha to form 70-80 nucleotide long precursor miRNA (Pre-miRNA). Pre-miRNA when exported out to 
cytoplasm, dicer acts on it to form a mature miRNA. This biogenesis process is followed by loading of the 
guide strand of the mature miRNA onto RISC for binding to the 3’UTR of a target mRNA. 
 
generated as polycistronic primary transcripts. It is demonstrated by in-vivo and in-vitro studies 
that miRNA biogenesis takes place in two sequential steps: i) formation of 70-80nt long 
precursor miRNA (pre-miRNA) from primary miRNA (pri-miRNA) and ii) processing of pre-
miRNA into mature miRNA (Kim, 2005; Lee et al., 2002). Mature miRNA sequences are 
contained within regions of pri-miRNAs that fold back on themselves to form approximately 60-
80nt stem-loop structure as shown in the Fig.1.4.2a.  
In the first step, the primary miRNA is acted upon by a microprocessor unit that includes 
Drosha, a nuclease of the RNAse III family and its binding partner DGCR8 as core components, 
in the nucleus to form 70-80nt long pre-miRNA (Denli et al., 2004; Gregory et al., 2004). The 
short stem of ~22 base pairs and a 2 nucleotide 3’overhang of pre-miRNA are recognized by the 
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nuclear export factor exportin5 (Exp5) (Bohnsack et al., 2004; Lund et al., 2004) to promote the 
correct and efficient processing of precursors in the generation of mature miRNAs. Exp5 may 
facilitate miRNA biogenesis by monitoring the integrity of pre-miRNAs and by promoting 
efficient release of pre-miRNAs from Drosha in the nucleus, where the level of RanGTP is high. 
The exported pre-miRNA undergoes further processing by one more RNA endonuclease III, 
Dicer, which removes the terminal loop, yielding a double-stranded 18-24nt RNA duplex. This 
duplex is further loaded onto a multicomponent protein complex known as the RNA-induced 
silencing complex (RISC). One of the strands of the duplex remains attached to the RISC while 
the other one gets destroyed. Selection of the RISC attached strand (referred to as guide strand) 
depends upon the base pairing at 5’end. The strand with less stable base pairing at 5’end becomes 
the mature miRNA (Khvorova et al., 2003; Schwarz et al., 2003).The fully processed miRNA 
duplexes are functionally equivalent to externally introduced siRNA. 
1.4.2.3 Mechanism of miRNA regulation: 
MiRNA guided strands, once loaded onto RISC, achieve gene silencing by either 
mRNA cleavage or translational repression of the target gene. The choice of mechanism depends 
upon the degree of complementarity between a miRNA and its target (Hutvagner and Zamore, 
2002; Zeng et al., 2003). Unlike siRNAs, miRNAs in vertebrates usually recognize one or more 
imperfectly complementary binding sites in the target mRNA 3’UTR. The partial 
complementarity prevents the cleavage by RISC and results in translational repression of the 
mRNA. The core protein components of RISC that interact with miRNAs are the Argonaute 
(Ago) proteins (Carmell et al., 2002). Ago2 out of 4 members of Argonaute family (Ago1-4) is 
capable of directing the miRNA mediated mRNA cleavage (Liu et al., 2004; Meister et al., 2004). 
The PIWI domain of the Ago2 structurally resembles the RNase H and provides the endonuclease 
activity to RISC. Recently people have reported the probable mechanisms of inhibition of mRNA 
translation by miRNAs. It is proposed that the inhibition of mRNA takes place at the translation 
initiation step (Pillai et al., 2005). They demonstrated that endogenous let-7 
microribonucleoproteins (miRNPs) or the tethering of Ago proteins to reporter mRNAs in human 
cells inhibit translation initiation. M7G-cap-independent translation is not subject to repression, 
suggesting that miRNPs interfere with recognition of the cap. The other probable mechanism is 
inhibition at the translation elongation step, wherein translational repression by miRNAs is 
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primarily due to ribosome drop off during elongation of translation (Petersen et al., 2006). The 
data demonstrated that gene silencing occurs before completion of the nascent polypeptide chain. 
In addition, silencing by short RNAs causes a decrease in translational readthrough at a stop 
codon, and ribosomes on repressed mRNAs dissociate more rapidly after a block of initiation of 
translation than those on normal mRNAs. Thus, miRNAs regulate the expression of their target 
genes post-transcriptionally by translational repression. 
1.4.2.4 MiRNAs in cancer: 
Till date, hundreds of miRNAs have been identified in human genome. Many of 
these miRNAs have been implicated in different diseases including cancers. Since miRNAs can 
simulatenously regulate the expression of a number of target genes, deregulation of a single 
miRNA may have a strong impact on important regulatory pathways in cancer. Kent and Mendell 
reviewed different reports which have shown the dysregulation of miRNAs in diverse cancers.  
(Kent and Mendell, 2006).Ongoing research in the field of miRNAs demonstrate the function of 
miRNAs as tumor supressors or oncogenes in different cancers. Interestingly, it was recently 
shown that 50% of annotated human miRNAs are located at fragile sites, as well as in minimal 
regions of loss of heterozygosity, minimal regions of amplification (minimal amplicons), or 
common breakpoint regions (Calin et al., 2004b) of human chromosomes which indicates a direct 
association of miRNAs with cancer progression.  
 MiRNAs as oncogenes: 
As discussed above, miRNAs negatively regulate the expression of their target genes, 
miRNAs acting as oncogenes downregulate the expression of their tumor suppressor targets 
leading to oncogenesis. Sonoki and colleagues reported a patient with precursor-B-cell acute 
lympho-blastic leukemia who carried an insertion of pre-miRNA into the IgH locus (Sonoki et 
al., 2005) and supported the role of miRNAs as oncogenic microRNAs termed oncomirs in 
cancer. BIC/miR-155 was the first miRNA transcript shown to possess oncogenic or tumor 
promoting activity (Eis et al., 2005). Overexpression of BIC/miR-155 has consistently been 
observed in tumors such as breast, lung, colon and thyroid cancers including B-cell lymphoma 
(Eis et al., 2005; He et al., 2005a; Volinia et al., 2006). It was shown that miR-155 can act as an 
oncogene in lymphoma using an animal model (Costinean et al., 2006). E(µ)-mmu-miR155 
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transgenic mice were shown to exhibit pre-B cell proliferation followed by lymphomagenesis. 
miR-21 is also shown to act as antiapoptotic gene in numerous cancers including glioblastoma. 
Markedly elevated miR-21 levels have been observed in human glioblastoma tumor tissues, 
primary tumor cultures, and in glioblastoma cell lines compared with nonneoplastic fetal and 
adult brain tissues and primary cultured neurons and astrocytes (Chan et al., 2005). Recently, it 
has been reported that miR-21 regulates multiple genes associated with glioma cell apoptosis, 
migration, and invasiveness, including the RECK and TIMP3 genes, which are suppressors of 
malignancy and inhibitors of matrix metalloproteinases (MMPs) (Gabriely et al., 2008). Like 
miR-155 and miR-21, there are many more miRNAs that are proven to be oncomirs. 
In addition to miRNAs themselves, the components associated with them such as Ago 
proteins also act as an antiapoptotic genes. For example, expression of Ago1 in developing lung 
and kidney and its increased expression in renal tumors that lack the Wilms-tumour suppressor 
gene, WT1 indicate its role in the differentiation of these tissues during embryogenesis (Carmell 
et al., 2002). An additional Ago gene, HIWI is mapped to the locus 12q24.33 which is a locus 
that is associated with testicular germ-cell cancers (Qiao et al., 2002).  
MiRNAs as tumor-suppressors: 
Unlike oncomirs, miRNAs acting as tumor suppressors downregulate various oncogenes 
and inhibit the process of tumor progression. miR-15a and miR-16-1 are some of the first 
miRNAs shown to be causatively related to cancer development. Human homologs of the 
C.elegans let-7 miRNA are also been reported to have tumor suppressor activity. Mendell 
reviewed that humans possess twelve let-7 homologs organized in eight distinct clusters. Further 
it was reported that at least four of these clusters are located in genomic regions known to be 
deleted in cancer (Calin et al., 2004b). It has been demonstrated that let-7 expression is lower in 
lung tumors than in normal lung tissue, while RAS protein is significantly higher in lung tumors, 
providing a possible mechanism for let-7 in cancer (Johnson et al., 2005). The 3’UTR of the RAS 
gene bears multiple let-7 complementary sites allowing let-7 to regulate RAS expression. Further, 
miRNAs of the let-7 family are also proven to be involved in gastric cancer. They are proposed to 
target the HMGA2 gene and reduce its expression leading to inhibition of tumor invasiveness 
(Motoyama et al., 2008). Decreased expression of miR-143 and miR-145 has been demonstrated 
to be a frequent feature of colorectal tumors (Michael et al., 2003). These miRNAs are known to 
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be contained within a genomic interval frequently deleted in myelodysplastic syndrome (Calin et 
al., 2004a). It was later demonstrated that these two miRNAs are suppressive to cell growth in 
cervical cancer. Thus, further insights into the role of microRNAs and the identification of 
microRNA::target interactions will be important for designing therapeutic drugs for diseases 
including cancers especially in cases which present deregulation of microRNA mediated control 
of gene expression as a pathological event. 
1.4.2.5 MiRNAs in cell cycle regulation: 
In addition to oncogenesis, miRNAs play an important role in cell cycle regulation 
though the mechanism is still not uncovered. They may participate in cell apoptosis, survival and 
differentiation. MiRNAs involved in cell cycle regulation are a part of the cell cycle regulatory 
pathways and machinery. MiRNAs have been shown to be intricately linked to the regulation of 
cell cycle regulatory genes and the disruption of this fine-tuned apparatus has been linked to 
cancer. Recently, there have been many reports indicating the oncogenic potential of miR-221 
and miR-222 by increased cell proliferation in cancers such as thyroid, prostate cancer and 
glioblastoma (Galardi et al., 2007; Gillies and Lorimer, 2007; le Sage et al., 2007; Visone et al., 
2007). These miRNAs target the cell cycle suppressive p27 gene thereby increasing the cell 
proliferation and tumor progression. Ricardo and colleagues extended these studies by showing 
that these miRNAs are up-regulated upon exit from quiescence and they target p57 in addition to 
p27. (Medina et al., 2008). Another miRNA, miR-34a has also been involved in cell cycle 
regulation through p53 pathway. It is the direct target of p53, and induced as a transcriptional 
activation by p53. Expression of miR-34a causes dramatic reprogramming of gene expression 
and promotes apoptosis. Much like the known set of p53-regulated genes, miR-34a-responsive 
genes are highly enriched for those that regulate cell cycle progression, apoptosis, DNA repair, 
and angiogenesis (Chang et al., 2007; Raver-Shapira et al., 2007).Moreover, deletion of the 
chromosomal region 1p36 where the miRNA transcript is located is a common feature of 
numerous human cancers including neuroblastoma and pancreatic cancer which makes it an 
attractive candidate tumor suppressor. Recent studies showed decreased expression of miR-34a in 
colon cancer patients (Tazawa et al., 2007) and also evidenced that miR-34a is a potent 
suppressor of proliferation through modulation of E2F signaling pathway. Thus, miR-34a 
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participates and fine tunes the program of genes involved in p53 mediated cell apoptosis. There 
are many such miRNAs that participate in cell proliferation, apoptosis and senescence. 
1.4.2.6 MiR-15a and miR-16-1: 
MiR-15a and miR-16-1 are some of the first miRNAs causally linked to cancer 
development as mentioned above. These are clustered together on human chromosome 13q14, 
the locus that is deleted in over half of B-cell chronic lymphocytic leukemia (CLL) cases and 
there has been significant effort to identify the putative tumor-suppressor genes located within 
this interval. Detailed deletion and expression analysis showed that miR-15a and miR-16-1 are 
located within a 30-kb region (13q14) which is recurrently lost in CLL, and that both genes are 
deleted or down-regulated in 68% of CLL cases (Calin et al., 2002).The germ-line mutation near 
miR-16-1 present in CLL cases is associated with reduced expression of these miRNAs though 
underlying mechanism of this effect is unclear. The role of these two miRNAs in tumorigenesis is 
revealed as they directly target the antiapoptotic gene, BCL2. This suggests that loss of function 
of miR-16-1 and miR-15a promotes increased expression of BCL2 leading to abnormal survival 
of CLL cells. Further reports have shown the frequent 13q14 deletions in other malignancies 
including mantle cell lymphoma, multiple myeloma and prostate cancer (Dong et al., 2001). All 
these observations suggest the probable tumor suppressive function of miR-15a and miR-16-1 in 
numerous cancers. 
 Apart from BCL2, some transcripts containing AREs are shown to be targeted by miR-
15a and miR-16-1. These miRNAs seem to recognize and rapidly degrade those transcripts. 
AREs in the 3’UTR of these unstable mRNAs dictate their decay. Dicer1, Ago1 and Ago2, the 
components of miRNA processing and function are reported to be required for the degradation of 
mRNA containing AU-rich sequences of tumor necrosis factor-alpha. It is further observed that 
miR16, a human miRNA containing an UAAAUAUU sequence that is complementary to ARE 
sequences, is required for ARE-RNA turnover (Jing et al., 2005). The role of miR16 in ARE-
RNA decay is sequence-specific and requires the ARE binding protein tristetraprolin (TTP). 
miRNA targeting of ARE, therefore, appears to be an essential step in tumorigenesis thus loss of 
ARE-mediated decay would be expected to increase the expression of some proto-oncogenes 
such as c-Fos, c-Myc and cyclin D1 which have AREs (Chen and Shyu, 1995). Moreover, miR-
16 induces cell cycle arrest at G1 phase by regulating multiple downstream effectors 
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simultaneously (Liu et al., 2008). Recently, it was demonstrated that miR-16 downregulates 
cyclin D1, cyclin D3, cyclin E1 and CDK6 which are involved in G1 to S transition in cell cycle, 
leading to inhibition of cell proliferation. MiR-16 has also been shown to promote apoptosis in 
cell dependent manner. 
1.4.2.7 MiR-17-92 cluster miRNAs: 
A well studied miRNA cluster, closely associated with different cancers is the 
miR-17-92 cluster. This cluster of six miRNAs, miR-17-5p, miR-20a, miR-19a, miR-19b, miR-
18a and miR-92 is located at 13q31-32. The primary transcript encoding miR-17 cluster miRNAs 
occupies around 1kb of genomic locus forming c13orf25.  
Fig.1.4.2b Schematic representation of the miR-17, miR-106a and miR-106b clusters. (figure from O’Donnell 
KA., Nature,2005) These are the three paralog clusters of miRNAs found in mammals on chromosome 13, X 
chromosome and on chromosome 7. The position of a mature miRNA is indicated by a dark box in a colored 
box with the name of a mature miRNA on top of the box. 
 
This genomic locus is known to be amplified in multiple haematologic malignancies such 
as B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and primary cutaneous 
lymphoma (Ota et al., 2004; Rinaldi et al., 2007). MiRNAs of mir-17-92 family are 
overexpressed in lymphoma cell lines harbouring the amplification of this genomic region (He et 
al., 2005b). The significance of this cluster of miRNAs in cancer is further strengthened by the 
observation that the transcription of the mir-17 cluster is directly activated by c-myc (O'Donnell 
et al., 2005). C-myc binds directly to the transcript of the mir-17 cluster and activates it. Further, 
miR-17-5p and miR-20a bind to the 3’UTR of the E2F1 transcription factor and decrease its 
protein expression. Thus, c-myc simultaneously activates E2F1 transcription and limits its 
translation, allowing a tightly controlled proliferative signal. Independently, Tagawa et al. 
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reported that the deregulation of miR-17 cluster and c-myc synergistically contribute to 
aggressive cancer development (Tagawa et al., 2007). They showed that nude mice injected with 
rat-1 cells transfected with miR-17 cluster along with c-myc present more accelerated tumor 
growth than those injected with myc transfectant cells. In another study, expression of miR-17 
was demonstrated to increase proliferation in lung cancer cell line (Hayashita et al., 2005). 
Recently, a novel cyclin D1/miR-17/20a feedback loop has been demonstrated through which 
cyclin D1 induces miR-17-5p and miR-20a. Cyclin D1 binds to the miR-17 cluster promoter 
regulatory region and induces its expression, in turn miR-17-5p and miR-20a bind to the 
complementary site in the 3’UTR of cyclin D1 leading to inhibition of proliferation in breast 
cancer cells (Yu et al., 2008).  
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1.5 Aim of the study: 
The dysregulation of cell cycle control is one of the fundamental aspects of cancers. 
Unlike normal cells, tumor cells proliferate as they are no longer subject to proliferation-
inhibitory influences. Several components of the cell cycle regulatory machinery are targets for 
aberrant alterations leading to malignancy. Cyclin D1 is one such candidate which has been 
shown to be involved in tumorigenesis. The role of this gene in cancer can be gauged from its 
frequent dysregulation due to mutations, activation or overexpression in several human cancers 
such as breast cancer, small cell lung cancer, neuroblastoma and mantle cell lymphoma (MCL). 
In MCL, the characteristic t(11;14) translocation juxtaposes the cyclin D1 gene downstream of 
the immunoglobulin heavy chain enhancer that leads to overexpression of cyclin D1. Even 
though mutations that alter the coding sequence of this gene have rarely been reported in cancer, 
there are several reports that point to somatic mutations in the 3’UTR of the cyclin D1 mRNA   
although the contribution of this 3’UTR loss to the malignant process is underappreciated and 
unexplored. The pathological role of 3’UTR mutations in various diseases is becoming 
increasingly apparent making this an attractive regulatory region for systematic exploration in 
various diseases. The purpose of the study is the assessment of the regulatory potential of the 
cyclin D1 3’UTR, the characterization of various elements in the 3’UTR and their contribution to 
cyclin D1 expression, and the elucidation of the effect of the loss of this region on cyclin D1 
expression and function. 
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Materials 
 
 
2.1 Mammalian cell lines: 
HeLa:   Human cervical cancer cell line 
A549:   Human lung carcinoma cell line  
MCF-7:   Human breast adenocarcinoma cell line 
MDA-MB-453:  Human breast carcinoma cell line-(procured from DSMZ, Europe) 
Phoenix Eco:   293 derived viral packaging cell line (kind gift from Dr. Slany, Erlangen) 
NIH3T3:   Mouse fibroblast cell line 
IEC-18:   Rat intestinal epithelial cell line-(procured from DSMZ, Europe) 
 
2.2 Media and reagents: 
2.2.1 Cell and tissue culture: 
Media: Dulbecco’s Modified Eagle’s Medium (DMEM) 4.5 g/l glucose, l-glutamine, without 
sodium pyruvate and 3.7 g/l NaHCO3 and Roswell-Park-Memorial-Institute 1640 (RPMI1640) 
with L-Glutamine and 2.0g/l NaHCO3 Medium (PAN Biotech GmbH, Aidenbach, Germany) 
Fetal Bovine Serum (FBS): 0.1 µm sterile filtered (PAN Biotech GmbH, Aidenbach, Germany) 
Trypsin/EDTA: 0.05/0.02% lg in PBS without Ca+2Mg+2 (PAN Biotech GmbH, 
Aidenbach,Germany) 
Dulbecco’s phosphate buffered saline (DPBS): With calcium and magnesium (PAN Biotech 
GmbH, Aidenbach, Germany) 
Penicillin/Streptomycin: 10,000 U Penicillin/ ml, 10 mg Streptomycin/ ml (PAN Biotech 
GmbH, Aidenbach, Germany) 
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Ciprofloxacin: Ciprofloxacin 400 solution, (Bayer AG, Leverkusen, Germany) 
Polyfect transfection reagent: Reagent for DNA transfection in cell lines (Qiagen GmbH, 
Hilden, Germany) 
Lipofectamine 2000 reagent: Reagent for miRNA and siRNA transfections in cell lines 
(Invitrogen, Carlsbad, CA) 
Pre-miR miRNA Precursor Molecules (Pre-miRs): (Ambion, Cambridgeshire, UK) 
Calcium chloride solution for transfection: 2.5 M CaCl2 (Sigma-Aldrich, St. Louis, MO) 
solution in water. 
Hepes Buffered Saline: (HBS) (Invitrogen, Carlsbad, CA) 
Protamine sulfate: (Salamine) from Salmon, cell culture tested (Sigma-Aldrich, St. Louis, MO) 
5 mg/ml stock solution 
Propidium iodide solution (PI): 50µg per ml solution for cell cycle analysis (Sigma-Aldrich, 
Steinheim) 
RNase A solution: 50mg per ml solution for cell cycle analysis (Invitrogen Life Technologies, 
Carlsbad, CA) 
Ethanol: For fixing of cells in cell cycle analysis (Merck KGaA, Darmstadt, Germany) 
Fluorescence Activated Cell Sorting (FACS) buffer: 2%FBS and 2µg/ml PI in PBS. 
Trypan blue stain: Trypan blue stain 0.4% for cell proliferation assay to check the viability of 
cells (Invitrogen, Carlsbad, CA) 
Cell scrapers: 25 cm sterile cell scrapers (Sarstedt, Newton, NC) 
Cell culture pipettes (2, 5, 10 and 25 ml): Sterile disposable pipettes (Corning Inc., Corning, 
NY) 
Filtration units: Millex syringe driven filter units 0.22 μm and 0.45 μm filters 
(Millipore,Billerica, MA) 
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Cell culture plates and dishes: Sterile 6 well plates (Sarstedt, Numbrecht, Germany) 100 mm x 
20 mm dishes for adherent cells (Corning Inc., Corning, NY, USA), and Tissue culture flasks (T-
75 PE vented cap) for adherent cells (Sarstedt, Numbrecht, Germany) 
2.2.2 Molecular biology: 
Agarose: Electrophoresis grade (Invitrogen life technologies, Carlsbad, Germany)) 
Gel elution of DNA and PCR or DNA cleanup: Gel elution and PCR purification kit for DNA 
elution from gels and clean up of PCRs (Qiagen GmbH, Hilden, Germany) 
Small-scale plasmid preparation: GFX miniprep kit for isolation of plasmid DNA from 
bacteria (Amersham Biosciences GmbH, Freiburg, Germany) 
Endo free Plasmid Maxi Kit: Maxi prep kit for isolation of DNA from bacteria (Qiagen GmbH, 
Hilden, Germany) 
RNeasy Mini Kit (250): RNA isolation from cells (Qiagen GmbH, Hilden, Germany) 
RNase-Free DNase Set (50): For removal of DNA during RNA isolation (Qiagen GmbH, 
Hilden, Germany) 
Mutagenesis kits: QuickChange II XL Site-Directed Mutagenesis kit for single site mutagenesis 
and QuickChange multi Site-Directed Mutagenesis kit (Stratagene, La Jolla CA, USA) 
Molecular weight markers: Nucleic acid size standards, 1 kb ladder, 1 kb plus ladder and 100 
bp ladder (Invitrogen, Carlsbad, CA) 
Enzymes: XbaI, ScaI, PstI, EcoRI, BamH1 and HindIII, all from New England Biolabs (NEB, 
Beverly, MA) Calf intestine phosphatase (CIP) and T4 DNA Ligase from Promega Corporation, 
Madison WI, USA 
DNA polymerase: Ampli Taq Gold (250 units) 5 U/µl (Applied Biosystems, Foster City, CA 
USA ) and Pfu Turbo (Stratagene, La Jolla CA, USA) 
DMSO: Reagent for freezing cell lines (Sigma-Aldrich-Chemie GmbH, Steinheim, Germany) 
dNTP mix: 100 mM each of dATP, dTTP, dCTP and dGTP (Invitrogen, Carlsbad, CA) 
MgCl2 solution: 25mM MgCl2 solution (Applied Biosystems, Foster City, CA USA) 
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PCR buffer: 10X PCR Gold Buffer (Applied Biosystems, Foster City, CA USA) 
RT-PCR kit: Gene Amp Gold RNA PCR Core kit (PE Biosystems, Foster City, USA) 
ABsolute SYBR Green ROX Mix: For RQ-PCR reaction for cyclin D1 mRNA expression 
analysis (Thermo Fisher Scientific Germany Co & Ltd., Bonn, Germany) 
Reporter assay kit: Dual-Luciferase Reporter Assay System (Promega Corporation, Madison 
WI, USA) 
2.2.2.1 Plasmids: 
MSCV-IRES-GFP (pMIG): A modified form of the MSCV vector, it contains a bicistronic GFP 
expression cassette with an internal ribosomal entry site.  
pEYFP-N1: Mammalian expression vector used for tagging genes with fluorescent reporter 
(Invitrogen, Carlsbad, CA) 
pGL3-Control: Firefly luciferase expression vector for dual luciferase reporter assay (Promega 
Corporation, Madison WI, USA) 
pGEM-T: Cloning vector (Promega Corporation, Madison WI, USA) 
pcDNA3.1/V5-His-TOPO: Expression vector used for cloning the miR-17-92 cluster region 
(Invitrogen, Carlsbad, CA) 
pRL-null: Renilla luciferase expression vector for dual luciferase reporter assay (Promega 
Corporation, Madison WI, USA) 
2.2.2.2 Oligonucleotides: 
All nucleotides were synthesized by Metabion AG, Martinsried, Germany. 
Cloning primers: 
CCND1 3’UTR-Fw CGCTCTAGAGATACCAGAAGGGAAAGCTTC 
CCND1 3’UTR-R(3191) GGGGTTTTACCAGTTTTATTT 
Cyd1_1kb_cDNA_Fw GGCGAATTCCACACGGACTACAGGGGAGTT 
Cyd1_1kb_cDNA_R2 GCGGGATCCCGGATGTCCACGTCCCGCAC 
D1_miR_clus1_Fw GGCTCTAGAACCTGTTTATGAGATGCTG 
D1_miR_clus1_Rev CGCTCTAGACCTACACCTATTGGACTGAA 
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D1_miR_clus2_Fw CGGTCTAGACTTATTGCGCTGCTACCGTT 
D1_miR_clus2_Rev GCCTCTAGACATGGCTAAGTGAAGCATGAG 
cyd1AURE-xhoI Fw CGGCTCGAGGATGTTTCACACCGGAAGG 
cyd1AURE-xhoI Rev CCGCTCGAGCCTTCAACACTTCCTCCTAAAT 
pcDNA6-int-Rev GTTAGGGATAGGCTTACCTTCG 
 
Mutagenesis primers: 
Cy1-3utr-1insert_Fw CTACAGATGATAGAGGATTTTATACCCCAATAAATCAACTCGTTTTTATAT 
Cy1-3utr-1insert_Rev ATATAAAAACGAGTTGATTTATTGGGGTATAAAATCCTCTATCATCTGTAG 
Cy1-3utr-3delns_Fw GTGCTACAGATGATAGAGGATTTTATACCCCAATAAACTCGTTTTTATATTAATG 
Cy1-3utr-3delns_Rev CATTAATATAAAAACGAGTTTATTGGGGTATAAAATCCTCTATCATCTGTAGCAC 
AUREmut t1425c_t1427g ACACTAAAATATATAATTTATAGTTAAGGCTAAAAAGTATACTGATTGCAGAGGATGTTCATAAGG 
AUREmut t1459c_t1461g GGATGTTCATAAGGCCAGTATGACTGATAAATGCAATCTCCCCTTGATT 
AUREmut t1483c_t1485g TTTATAAATGCAATCTCCCCTTGACTGAAACACACAGATACACACACACAC 
AUREmut t1400c_t1402g TTCACACCGGAAGGTTTTTAAACACTAAAATATATAACTGATAGTTAAGGCTAAAAAGTATAC 
AUREmut t1548c_t1550g ACAAACCTTCTGCCTTTGATGTTACAGACTGAATACAGTTTATTTTTAAAGATAGATCC 
AUREmut t1815c_t1817g-
Fw 
CACATCTTGGCTATGTAATTCTTGTAATTTTTACTGAGGA
AGTGTTGAAGGGA 
 
AUREmut t1815c_t1817g-
Rev 
TCCCTTCAACACTTCCTCAGTAAAAATTACAAGAATTAC
ATAGCCAAGATGTG 
 
AUREmut t2669c_t2671g-
Fw 
TGTTTGTTATTGTTTTGTTAATTACACCATAATGCTAACT
GAAAGAGACTCCAAATCTCAATG 
 
AUREmut t2669c_t2671g-
Rev 
CATTGAGATTTGGAGTCTCTTTCAGTTAGCATTATGGTGT
AATTAACAAAACAATAACAAACA 
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miR17seed del_Fw CTAAAACCATTCCATTTCCAAGTTCAGTCCAATAGGTGTAGGAA 
miR17seed del_Rev TTCCTACACCTATTGGACTGAACTTGGAAATGGAATGGTTTTAG 
miR15-16seed del-1_Fw GCTCCATTTTCTTATTGCGTACCGTTGACTTCCAGGCA 
miR15-16seed del-1_Rev TGCCTGGAAGTCAACGGTACGCAATAAGAAAATGGAGC 
miR15-16seed del-2_Fw CTGTGTATCTCTTTCACATTGTTTGTATTGGAGGATCAGTTTTTTGTTTT 
miR15-16seed del-2_Rev AAAACAAAAAACTGATCCTCCAATACAAACAATGTGAAAGAGATACACAG 
 
Sequencing primers: 
cyD1 3'UTR-F2 CCCCCTTCCATCTCTGACTT 
cyD1 3'UTR-R7 ACGTCAGCCTCCACACTCTT 
luc-Cfor AGAGAGATCCTCATAAAGGC 
cyD1 3'UTR-R5 TCATCCTGGCAATGTGAGAA 
cyD1 3'UTR-F7 CCTAAGTTCGGTTCCGATGA 
cyD1 3'UTR-R8 CCAAAGCAGGCAGAACCTG 
MIG Fw TCCCTTTATCCAGCCCTCACTC 
 
Real time RT-PCR primers: 
CCND1-RT-Fw AATGACCCCGCACGATTTC 
CCND1-RT-Rev TCAGGTTCAGGCCTTGCAC 
TBP-RT-Fw GCACAGGAGCCAAGAGTGAA
TBP-RT-Rev TCACAGCTCCCCACCATGTT 
 
Pre-miRs: 
All Pre-miRs were synthesised by Ambion Ltd. Cambridgeshire, UK 
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Pre-miRs (microRNA mimics) sequences: 
  Mature sequences corresponding to Pre-miRs 
Pre miR-15a UAGCAGCACAUAAUGGUUUGUG 
Pre miR-16-1 UAGCAGCACGUAAAUAUUGGCG 
Pre miR-95 UUCAACGGGUAUUUAUUGAGCA 
 
 
 
2.3 Western blotting: 
2.3.1 Reagents for western blotting: 
Protein molecular weight markers: SeeBlue®Plus2 Prestained Standard (Invitrogen GmbH, 
Karlsruhe, Germany) 
Bio-Rad protein assay Standard I: Lyophilized Bovine Plasma Gamma Globulin (Bio Rad 
Laboratories, Munich, Germany) 
Dye reagent concentrate: Protein assay solution for protein estimation (Bio Rad Laboratories, 
Munich, Germany) 
30% acrylamide mix: Rotiphorese Gel 30 (37.5:1) (Carl Roth GmbH, Karlsruhe, Germany) 
TEMED: For SDS-polyacrylamide gel preparation (Sigma Aldrich Chemie GmbH, Germany) 
2X SDS loading buffer: 125 mM Tris pH 6.8, 4% SDS, 20% Glycerol, 10% 2-Mercapto β-
Ethanol and a pinch of Bromophenol blue 
RIPA lysis buffer: 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15M NaCl, 5mM EDTA 
and 50mM Tris pH 8.0 
Milk powder: Blotting grade (Carl Roth GmbH, Karlsruhe, Germany) 
Hydrogen peroxide: For ECL solution (Sigma Aldrich Chemie GmbH, Germany) 
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Standard Buffer solutions:  
Beta-Mercaptoethanol 360µl 
1M Tris-HCl – buffer 
pH6.6 2.5ml 
SDS (20% w/v) 4ml 
Membrane stripping-buffer 
Distilled water to make 40ml 
Tris 150g 
Glycin 720g 
SDS 50g 
10x SDS-PAGE buffer 
Distilled water to make 5l 
Tris 15.15g 
Glycin 75g 
Methanol 1l 
Western blot transfer-buffer 
Distilled water to make 5l 
Tris 908g 
Distilled water to make 5l 1.5M Tris-HCl (pH8.8 or pH6.8) 
(pH adjusted with HCl)   
Tris 12.11g 
Sodium chloride 87.66g 
Distilled water to make 1l 
10x TBS pH8.0 
(pH adjusted with HCl)   
 
Antibodies: 
 
 Name Company Dilutions used 
Rabbit polyclonal anti-GFP Invitrogen, Carlsbad, CA 1/ 5000 
Mouse anti-human Cyclin D1 BD Biosciences, Pharmingen, NJ 1/ 500 
Rabbit anti-Actin Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 1/ 5000 
Bovine anti-rabbit IgG-HRP Santa Cruz Biotech. Inc., CA 1/ 5000 
Bovine anti-mouse IgG-HRP Santa Cruz Biotech. Inc., CA 1/ 5000 
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2.4 Instruments: 
PCR and RT-PCR: GeneAmp PCR System 9700 for cloning PCR and RT-PCR (Applied 
biosystems, Foster City, USA) 
Flow Cytometry: BD FACS calibur system (BD Biosciences, Palo Alto, CA) 
Fluorescence Activated Cell Sorting: BD FACSVantage SE System (BD Biosciences, Palo 
Alto, CA) 
Fluorescence microscope: Axiovert 200M (Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany) 
Microscope: Leitz Diavert Inverted Microscope (Opto Sonderbedarf GmbH, Munich, Germany) 
Protein Electrophoresis: Power Pac 300 and power pac 1000 (Bio Rad Laboratories, Munich, 
Germany) 
Dual Luciferase Assay Reporter measurements: Orion II microplate luminometer (Berthold 
Detection Systems GmbH, Pforzheim, Germany)  
Blot development: Phospho imager CAWOMAT 2000 IR (CAWO Photochemisces Werk 
GmbH, Schrobenhausen, Germany) 
 
2.5 Software: 
The analysis of the cyclin D1 3’UTR for putative microRNA binding sites was performed 
using the TargetScan and PicTar microRNA target prediction software tracks loaded on the 
University of California Santa Cruz Genome Browser May 2004 (hg17) assembly (URL: 
http://genome.ucsc.edu). The analysis for the AURE sequences was performed by manually 
scanning AUUUA pentamers in the 3’UTR sequence of the human cyclin D1 gene downloaded 
from the University of California Santa Cruz Genome Browser May 2004 (hg17) assembly as 
well. The CellQuest software (BD biosciences, Paulo Alto CA, USA) was used for the 
calculation of mean fluorescent intensities (MFI) of YFP from different CCND1-YFP constructs 
transiently transfected into HeLa cells. The ModFit LT program (Verity Software House, 
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Topsham, ME, USA) was used for the cell cycle analysis of IEC-18 cells transduced with cyclin 
D1. Primers were designed using the Primer3 program, Whitehead Institute, Massachusetts 
Institute for Technology, MA (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
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Methods 
 
 
3.1 Cloning of constructs: 
Cyclin D1 (CCND1) 3’UTR: 
The 3.19 kb CCND1 3’UTR was amplified from the genomic DNA of peripheral blood 
cells isolated from a healthy consenting individual using the primers CCND1 3’UTR-Fw and 
CCND1 3’UTR-R(3191), by Ampli Taq Gold DNA polymerase enzyme, using the following 
PCR program: 
Temperature (oC) Time  Cycles 
95 10 minutes 1 
95 45 seconds   
56 45 seconds 8 
72 3 minutes   
95 45 seconds   
58 45 seconds 8 
72 3 minutes   
72 10 minutes 1 
4 hold  
 
The amplicon was then ligated to the pGEM-T vector using T4 DNA ligase and incubated 
overnight at 4°C. After screening colonies transformed with the ligation mixture, the appropriate 
clone (pGEM-T-UTR) was identified by digestion of the minipreps by the restriction enzymes 
Pst I and XbaI. This clone was completely sequenced by cyD1 3’UTR-F7, cyD1 3’UTR-R5 and 
cyD1 3’UTR-R7 sequencing primers and subsequently sub-cloned as an XbaI digested fragment 
into the dephosphorylated XbaI site of the pGL3-Control. Competent E.coli (DH5α) were used 
for transformation of the ligation mixture and colonies were identified by colony PCR using the 
primers cyD1 3’UTR-F7 and cyD1 3’UTR-R8. The PCR program used was as follows:  
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Temperature (oC) Time  Cycles 
94 2 minutes 1 
94 30 seconds  
55 30 seconds 25 
72 45 seconds  
72 5 minutes 1 
4 hold  
 
Plasmid DNA was prepared from colonies showing amplification with the aforementioned 
primers using the small scale plasmid isolation kit. All the mini preps were then digested with 
Hind III to identify clones with the CCND1 3’UTR in the correct 5’to 3’ orientation with respect 
to the luciferase gene. The correct clone harbouring the full length 3’UTR (Flu) was sequenced 
completely using luc-Cfor and cyD1 3’UTR-F7 sequencing primers. 
CCND1 3’UTR fragments: 
 The region of CCND1 3’UTR including a highly conserved  miR-17-92 cluster binding 
site (reg-17-92) and a region complementary to the  two miR-15/16 binding sites (reg-15/16) 
were amplified from the full length cyclin D1 3’UTR clone (Flu) using the primer pairs 
D1_miR_clus1_Fw, D1_miR_clus1_Rev and D1_miR_clus2_Fw, D1_miR_clus2_Rev 
respectively. The PCR program used was as follows: 
Temperature (oC) Time  Cycles 
94 2 minutes 1 
94 45 seconds  
55 45 seconds 30 
72 1 minute  
72 5 minutes  
4 hold  
 
Both the above mentioned fragments (reg-17-92 and reg-15/16) were then digested with XbaI and 
ligated separately to the cut and dephosphorylated XbaI site of the pGL3-Control vector 
downstream of the luciferase gene. An individual colony PCR of the transformed ligation 
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mixtures was performed using the above respective cloning primers for the regions. The PCR 
program used was the same as that for cloning albeit with 20 cycles. The appropriate clones of 
the regions were identified by sequencing with the primer luc-Cfor. 
MiR-17 cluster and sensor plasmids: 
The miR-17 cluster was obtained as a clone in the pcDNA3.1/V5-His-TOPO expression 
vector. The sensor plasmids of miR-17-5p and miR-20a were made by cloning the sequences 
perfect complementary to the miR-17-5p and miR-20a miRNAs respectively in two tandem 
repeats into the pGL3-Control (O'Donnell et al., 2005). These constructs (CMV-miR-17 cluster, 
miR-17-5p-sensor and miR-20a-sensor) were a kind gift from Prof. Joshua Mendell at the Johns 
Hopkins Institute. 
MiR-15/16 expression plasmid: 
The miR-15/16 miRNAs cloned into expression plasmid (pLenti6-BLOCK-iT-DEST) 
(Linsley et al., 2007) were obtained as a kind gift from the Merck & Co., Inc.  
CCND1 CDS in peYFP-N1: 
The 1.2 kb CCND1 without 3’UTR (5’UTR and coding sequence) was first cloned into 
the pcDNA6/V5-HisA plasmid (CCND1 full-pcDNA6). CCND1 CDS was amplified using the 
cloning primers Cyd1_1kb_cDNA_Fw and Cyd1_1kb_cDNA_R2 from the aforementioned 
construct, using the following PCR program: 
Temperature (oC) Time  Cycles 
94 2 minutes 1 
94 45 seconds  
55 45 seconds 28 
72 1 minute  
72 5 minutes 1 
4 hold  
 
 The EcoRI, BamHI digested CCND1 CDS amplicon was further cloned into the EcoRI, BamHI 
digested peYFP-N1 vector fusing the cyclin D1 CDS in frame with the YFP at the N terminal end 
(CCND1 CDS-YFP). 
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CCND1 full gene into peYFP-N1 (CCND1 full-YFP): 
The CCND1 3’UTR was subcloned downstream of the YFP in the CCND1 CDS-peYFP-
N1 construct in a downstream XbaI site. For this, an XbaI - XbaI digested 3’UTR was ligated to 
the XbaI digested and dephosphorylated CCND1 CDS-YFP. Minipreps were made from the 
colonies picked from the transformed ligation mixture. The appropriate clone (CCND1 full-YFP) 
was confirmed by sequencing with the primer cyD1 3’UTR-R8. 
CCND1 full gene with ARE deletion into peYFP-N1 (ΔARE-YFP): 
 The ΔARE-YFP construct was cloned by ligating the two fragments of the CCND1 
3’UTR, The fragment before the first ARE sequence (F-1) and the one after the 6th ARE 
sequence (F-2) in the 3’UTR.  
 Firstly, the F-1 and F-2 were amplified from the Flu and CCND1 full-pcDNA6 
respectively. The primer pairs CCND1 3’UTR-Fw, cyd1AURE-xhoI Rev and cyd1AURE-xhoI 
Fw, pcDNA6-int-Rev were used for F-1 and F-2 respectively. The following PCR program was 
used for both the fragments: 
Temperature (oC) Time  Cycles 
94 2 minutes 1 
94 45 seconds  
55 45 seconds 30 
72 1:50 minutes  
72 5 minutes 1 
4 hold  
 
Both the amplicons were digested with XhoI and ligated using pGEM-T system for 1 hour at 
room temperature. Further this ligation mixture was used as a template to amplify CCND1 
3’UTR without ARE region using the primer set CCND1 3’UTR-Fw, pcDNA6-int-Rev with the 
following PCR program: 
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Temperature (oC) Time  Cycles 
94 5 minutes 1 
94 45 seconds  
55 45 seconds 32 
72 3 minutes  
72 10 minutes 1 
4 hold  
 
The amplicon was gel eluted and XbaI digested to clone into the CCND1 CDS-peYFP-N1 
construct.  
CCND1 full gene and CCND1 CDS into pMIG: 
The CCND1 full gene was sub-cloned into the MIG vector from CCND1 full-pcDNA6 
construct. The PmeI digested CCND1 full-pcDNA6 was cloned into the HpaI site of the pMIG. 
The ligation mix of pMIG and CCND1 full gene was transformed into the DH5α and minipreps 
were made. These were further digested with XhoI to check the orientation of the clones. The 
correct clone (CCND1 full-MIG) was reconfirmed by sequencing with MIG Fw primer. Further 
the CCND1 full-MIG construct was digested with XhoI to remove the XhoI- XhoI fragment of the 
3’UTR and religated at 4°c overnight to get the CCND1CDS-MIG construct (CCND1 without 
3’UTR in pMIG). 
 
3.2 Mutagenesis (CCND1 mutants): 
MCL patient mutations: 
The deletion of 3 bp ‘TCA’ or insertion of a nucleotide ‘A’ at the positions 309-311 and 
308 respectively in the CCND1 3’UTR are the mutations found in MCL patient samples 
(Wiestner et al., 2007). These two types of point mutations were made individually into CCND1 
full-peYFP construct using the QuickChange II XL Site-Directed Mutagenesis kit as per the 
manufacturer’s protocol. The primer sets Cy1-3utr-3delns_Fw, Cy1-3utr-3delns_Rev and Cy1-
3utr-1insert_Fw, Cy1-3utr-1insert_Rev were used for the deletion of 3 bp ‘TCA’ and insertion of 
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one nucleotide ‘A’ into the 100 ng of aforementioned construct. The following PCR program (as 
per the instructions in the manual) was used 
Segment Cycles Temperature (oC) Time 
1 1 95  1 minute 
2  95 50 seconds 
 18 60 50 seconds 
  68 1 minute/kb of plasmid length 
3 1 68 7 minutes 
 
The PCR product was digested with Dpn I restriction endonuclease (10U/µl) (provided in the kit) 
to digest the parental DNA template. The digestion is followed by the transformation into XL10-
Gold ultracompetent cells (provided in the kit) as per the protocol in the manual. The colonies 
from the agar plate were then inoculated into liquid cultures to make the minipreps. These 
minipreps were sequenced with cyD1 3’UTR-F2 primer to identify the appropriate mutants 
(CCND1-3del-YFP and CCND1-ins-YFP). 
ARE sequence mutations (Flu-7∆ARE):  
The pentamer sequence AUUUA is a signature motif of the ARE elements. 7 repeats of 
AUUUA sequences were mutated by substituting first U by C and the third one by G in each 
pentamer using the QuickChange Multi Site-Directed and Single Site directed Mutagenesis Kits. 
The cyclin D1 full gene with 5 mutated AREs in pGL3-Control vector (Flu- 5ΔARE) was made 
in two steps. firstly the AUREs at positions 1425-27, 1459-61 and 1483-85 were mutated using 
100 ng each of the 3 primers AUREmut t1425c_t1427g, AUREmut t1459c_t1461g and 
AUREmut t1483c_t1485g into 100 ng of Flu as per the manufactirer’s instructions. The PCR 
program (given in the manual) was as follows: 
Segment Cycles Temperature (oC) Time 
1 1 95  1 minute 
2  95  1 minute 
 30 55 1 minute 
  65 2 minutes/kb of plasmid length 
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The PCR product was digested with Dpn I restriction endonuclease (10U/µl) (provided in the kit) 
to digest the parental DNA template. The digestion is followed by the transformation into XL10-
Gold ultracompetent cells (provided in the kit) as per the protocol in the manual. The colonies 
from the agar plate were then inoculated into liquid cultures to make the minipreps. The 
minipreps were sequenced with cyD1 3’UTR-F12 to identify the correct mutant (Flu-3ΔARE). 
This same protocol including the PCR program was used to mutate further 2 ARE pentamers at 
positions 1400-02 and 1548-50 in the Flu-3ΔARE. 100 ng of Flu-3 ΔARE was mutated using 100 
ng each of the primers AUREmut t1400c_t1402g and AUREmut t1548c_t1550g. The appropriate 
mutant (Flu-5ΔARE) was identified by sequencing the minipreps with cyD1 3’UTR-R7. The 6th 
and the 7th repeats of the AUUUA pentamer at position 1815-17 and 2669-71bp respectively 
were mutated by QuickChange II XL Site-Directed Mutagenesis kit using the primer pairs: 
AUREmut t1815c_t1817g-Fw, AUREmut t1815c_t1817g-Rev and AUREmut t2669c_t2671g-
Fw, AUREmut t2669c_t2671g-Rev as per the manufacturer’s protocol and the mutant Flu-
7ΔARE was generated. 
Mutant of the reg-17-92 clone (reg-17-92-M): 
For mutations that generate mismatches in microRNA binding sites, 4 nucleotides of the 
sequence bearing perfect complementarity to the 7-8 nucleotide ‘seed’ sequence of the miR-
17/20a miRNAs was replaced by randomly chosen non-complementary nucleotides using the 
QuickChange II XL Site-Directed Mutagenesis Kit. The mutant reg-17-92-M was amplified from 
100 ng of reg-17-92 construct using the primers miR17seed del_Fw and miR17seed del_Rev 
with the PCR program mentioned in the section 3.2 for ARE sequence mutation, as per the 
manufacturer’s protocol. The PCR product was further digested with Dpn I and transformed into 
XL10-Gold ultracompetent cells. The correct clone was identified by sequencing the minipreps 
with luc-Cfor sequencing primer. 
Mutant of the reg-15/16 clone (reg-15/16-M3): 
The two binding sites of the miR-15/16 miRNAs in the reg-15/16 were mutated by 
replacing the 4 nucleotides in the seed sequence of the miR-15/16 miRNAs by randomly chosen 
non-comlementary nucleotides, sequentially using the QuickChange II XL Site-Directed 
Mutagenesis Kit. The first binding site was mutated using the primers miR15-16seed del-1_Fw 
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and miR15-16seed del-1_Rev using 100 ng of the reg-15/16 as the template. The protocol was 
the same as that used for the generation of reg-17-92-M mutant. The correct mutant (reg-15/16-
M1) was confirmed by sequencing using luc-Cfor primer.  
The reg-15/16-M1 was used as the template for mutating the second binding site. The primers 
miR15-16seed del-2_Fw and miR15-16seed del-2_Rev were used for the PCR and the protocol 
used to generate the mutant was same as the one mentioned for reg-15/16-M1 generation. The 
appropriate mutant (reg-15/16-M3) was identified by sequencing with luc-Cfor primer. 
 
3.3 Preparation of stable cell lines: 
3 x 106 Phoenix Eco cells were plated in a 10 cm dish and on the following day used for 
transient transfection. Medium was changed 4 hours prior to the transfection and 20 μg plasmid 
DNA each of the gene of interest was added to sterile water and a sterile solution of 100 μl 2.5M 
CaCl2 was added drop wise to the water-DNA mixture. The volume of water added initially was 
calculated so as to make the total volume 1 ml. This was added slowly to a tube containing 1 ml 
sterile Hepes buffered saline solution (pH 7.2). After gentle mixing and incubating at room 
temperature for 3-4 minutes, this mixture was added drop wise to the medium covering the whole 
plate and without agitating the cells. The medium was changed the next day and supernatant was 
collected from the cells every 12 hours (thrice totally) and fresh medium added. This supernatant 
was filtered with a 0.45 mm Millipore filter and stored as VCM at –80°C for later use or used 
directly to transduce NIH3T3 fibroblasts and IEC-18 epithelial cells. 
5x 104 NIH3T3 fibroblasts and IEC-18 cells were plated into 6 well plates one day 
prior to transduction. The next day, medium was withdrawn from these cells and 500 μl or 1 ml 
of fresh or frozen VCM was layered on top of the cells with the addition of a final concentration 
of 10 μg/ml protamine sulfate. Fresh medium was added after 4 hours and the transduction 
procedure was repeated every 12 hours for three-four times. The cells were expanded and two 
days were allowed for GFP expression. Green fluorescent cells were sorted using the 
fluorescence activated cell sorter (FACS) sorter and propagated. Using these protocols, CCND1 
 44
                                                                                                                         M  e  t  h  o  d  s   
 
 
CDS, only GFP and CCND1 full NIH3T3 and IEC-18 stable cell lines were constructed and used 
for experiments.  
  
3.4 Proliferation assay: 
Proliferation assay was performed in stable CCND1-NIH3T3 and CCND1-IEC-18 cell 
lines to check the phenotypes of the cells with CCND1 with and without 3’UTR. The cells 
expressing CCND1-CDS, CCND1 full and empty vector individually were plated at a density of 
1X105 each in 6 well plates and this was counted as day 0. The cells were trypsinized and living 
cells were counted every alternate day (on day2, day4, day6 and day8) using Trypan blue. The 
cell suspension and trypan blue are mixed in 1:1 proportion and the number of viable cells per 
milliliter of the cell suspension (cells /ml) was calculated using the following formula: 
Total no. of viable cells (104) = (No. of viable cells / 4) X dilution factor X10, 000 
  
3.5 Cell cycle analysis: 
 The effect of overexpressed CCND1 with or without 3’UTR on cell cycle was checked by 
cell cycle analysis in the stably transfected IEC-18 primary cell line. After sorting and 
propagating GFP positive cells expressing CCND1 with or without 3’UTR or empty vector pMIG 
Cells were harvested for cell cycle analysis. Approximately 1 x 106 cells were used for the 
analysis. These cells were washed with PBS twice and spun down for 5 min. at 1000 rpm. The 
supernatant was removed and the cells were resuspended in 50 µl of fresh PBS. 1 ml of ice cold 
80% ethanol was added dropwise with constant vortexing, mixed well followed by 30 min. 
incubation on ice. Cells were then pelleted by centrifugation for 5 min. at 1000 rpm. Cells were 
again washed twice with PBS to remove ethanol completely. Cell pellet was loosened by light 
vortex and 500 µl of 50 µg/ml PI solution was added with constant vortexing, followed by 
addition of 500 µl of 1mg / ml RNase A solution. Cells were then incubated in the dark for 30 
min. at room temperature and analysed on FACS caliber. The analysis was done using the 
software ModFit LT. 
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3.6 Western blotting: 
Sample preparation and cell lysis (total cell extract) 
 Western blotting was done to show the CCND1 protein expression in CCND1 full and 
CCND1 CDS-NIH3T3 and IEC-18 stable cell lines and the expression of the CCND1CDS and 
CCND1full-YFP constructs. This was also done to check the CCND1 protein expression in 
transiently transfected MCF-7 and MDA-MB-453 cell lines. The cells were lysed using 100 µl 
RIPA buffer with fresh added protease inhibitors and detached using a cell culture scraper. The 
cells with RIPA buffer were transferred to an Eppendorf microcentrifuge tube and mixed by 
inversion and kept on ice for 30 minutes. After the homogenization, the sample was centrifuged 
at 14000 rpm for 30 minutes at 4oc. After centrifugation, the supernatant was transferred to a new 
Eppendorf tube and either frozen at -80°C, or kept on ice for determination of protein 
concentration. As a control, Granta cells overexpressing CCND1 protein were used. Lysate was 
prepared using the method described above. 
Determination of Protein Concentration: 
The method used for measuring the protein concentration was the Bradford method. The 
assay is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein occurs. 
Both hydrophobic and ionic interactions stabilize the anionic form of the dye, causing a visible 
color change. The assay is useful since the extinction coefficient of a dye-albumin complex 
solution is constant over a 10-fold concentration range. Within the linear range of the assay (1-21 
µg/ml), the more protein present, the more Coomassie binds. The protein concentration of the 
sample was determined by comparison to values obtained for the measure of the known range of 
protein standards. The protein standard used was Bovine Plasma Gamma Globulin. Six different 
gamma globulin concentrations (1.4µg, 2.8µg, 7µg, 14µg and 21µg) were diluted in distilled 
water to a final volume of 800 µl. Two microliter of cell lysate was diluted in distilled water for 
the measure. 200 µl of Protein Assay solution (Dye reagent concentrate) was added to the tubes. 
The tubes were incubated at room temperature for 15 minutes and the content was further 
transferred to polystyrol cuvettes. A determination of the standard curve of the spectrophotometer 
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with distilled water and the protein standards was done using the specific program for protein in 
the spectrophotometer. The sample was measured following the standard curve determination. 
SDS PAGE of Cell Extracts: 
Total cell extract (TCE) proteins were separated on a denaturing gel consisting of 10% 
Tris-glycine gel and a 5% stacking gel. The concentration of the separation gel was chosen 
considering the size of CCND1 protein. The sample was homogenized and diluted 1:1 with 2x 
loading buffer and heated at 95oC for 2 minutes. 40 µg protein was loaded in each lane and the 
SeeBlue®Plus2 Prestained Standard in one of the lanes. The electrophoresis was performed in the 
1x SDS-PAGE buffer under 60 V for 30 minutes and 80 V for 1 hour and 30 minutes using 
Power pac 1000. 
Protein Blotting: 
During the electrophoresis, the PVDF membrane was wetted in mthanol for 30 seconds, 
rinsed with distilled water and equilibrated in western blot transfer buffer. The blotting papers (6 
for each gel) were equilibrated in western blot transfer buffer as well. After the electrophoresis, 
the gel was taken from the cassette and placed on the stack of 3 bloting papers and a PVDF 
membrane. 3 more blotting papers were stacked on the gel and the blotting was done at 250mA 
for 2 hours and 30 minutes. The observation of the high molecular weight proteins of the pre-
stained protein standard on the membrane was an indicator of successful transfer. 
Protein detection on the blotting membrane with HRP-marked antibodies:  
The antibody-detection of protein was performed following the instructions of the 
antibody’s supplier. After the transfer, the membrane was blocked to prevent non-specific 
binding of antibodies to the membrane by incubating with 5% milk solution in TBS with 0.05% 
Tween-20 (TBST) for one hour at room temperature.The membrane was further incubated with 
the primary antibody at 1:5000 dilution in 5%Albumin Fraction solution in TBST overnight at 
4oc. The concentration used for the antibodies was adjusted according to the intensity and 
background. After incubation with the primary antibody, the membrane was washed three times 
with TBST (each wash for 5 minutes) at room temperature on a roller. The secondary antibody 
conjugated with Horse Radish Peroxidase (HRP) was diluted 1:5000 in 5% milk TBST solution 
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and put on the membrane for 1 hour incubation at room temperature. The membrane was washed 
again three times with TBST on roller. To detect the antibodies on the membrane an ECL 
detection solution (4 ml SA solution, 1.2µl hydrogen peroxide and 400µl SB solution) was used. 
After washing, the ECL detection solution was put on the membrane for 2 minutes. The 
membrane was dried, covered with a plastic film and put in a cassette for exposure of the film. 
The film was put on the membrane in a dark room and the exposure was done at variable 
exposing times between 15 seconds and 1 minute, depending on the visualization signal 
observed. 
 
3.7 Reporter assays:  
The dual luciferase reporter assay system was used to show the direct and specific 
interaction between CCND1 3’UTR and miRNAs targeting it. HeLa cells were plated at a density 
of 3x105 cells per well in 6-well plates one day before transfection. pGL3-Control, Flu, reg-17-
92, reg-17-92-M, miR-17-5p-sensor, miR-20a-sensor, and CMV-miR-17 cluster were transfected 
transiently using  12 µl of Polyfect transfection reagent as described by the manufacturer in 
independent wells. Firefly luciferase activity from the Flu, pGL3-Control, reg-17-92, reg-17-92-
M and sensor plasmids and Renilla luciferase activity from the internal control plasmid pRL-null 
were determined 24 hour after the initiation of the transfection protocols using the Dual-
Luciferase reporter Assay System. Firefly luciferase activities were normalised to the Renilla 
luciferase values of pRL-null. Results are given as means ± S.E.M. of three independent 
experiments. The following DNA concentrations of the reporter constructs and expression 
plasmids were used for Polyfect transfections: 0.03 µg of the internal control pRL-null, 1.5µg of 
pGL3-Control, Flu, reg-17-92, reg-17-92-M, miR-17-5p-sensor, miR-20a-sensor each and 0.5µg 
of CMV-miR-17 cluster was cotransfected with each of the above reporter constructs. In the 
transfections without cotransfection of CMV-miR-17 cluster, empty vector pcDNA6/V5-HisA 
was included to equilize the amount of DNA in transfection set. 
The same reporter assays were performed with 1.5 µg of reg-15/16, reg-15/16-M3 each 
cotransfected with 50nM pre-miR-15a, pre-miR-16-1 and pre-miR-95 each. 3µl of Lipofectamine 
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2000 transfection reagent was used for the aforementioned tranfections. Firefly luciferase 
activities were normalised to the internal control Renilla luciferase values of pRL-null. 
 The dual luciferase reporter assays were performed also to study the effect of AREs on 
cyclin D1 regulation. 1.5µg of each of Flu-7ΔARE and Flu was cotransfected with the internal 
control 0.03µg of pRL-null using 12µl of polyfect and the aforementioned protocol of the dual 
reporter assay was used. 
 
3.8 Transient transfections and fluorescence microscopy: 
Twenty four hours before transfection, HeLa cells were plated at a density of 3x105 cells 
per well in 6-well plates. The cells then transiently transfected with 2µg of each of CCND1 full-
YFP, CCND1-CDS-YFP and ΔARE-YFP construct using 3µl of Lipofectamine 2000 as per the 
protocol described by the manufacturer. 18-20 hour post transfection the cells were observed 
under the fluorescence microscope (Axiovert 200M) (10X) for the fluorescence of the transfected 
cells. Similar transfection efficiencies could be obtained with the different constructs. The 
observed cells were trypsinized with 1 ml of Trypsin/EDTA per well and suspended in 1 ml of 
FACS buffer per sample for FACS analysis.  
 
3.9 Flow cytometry: 
Quantitative estimation of the difference between expression of CCND1 protein with and 
without 3’UTR was done by flow cytometric analysis of transiently transfected HeLa cell 
(mentioned in section 3.8). The cells in FACS buffer were analysed on the BD FACS Calibur 
System for YFP positivity using the YFP filter and histograms were plotted using the CellQuest 
software for the calculation of mean fluorescence intensity (MFI) of YFP. The mean fluorescent 
intensities of the constructs with different UTRs were compared. All experiments were performed 
in triplicates. 
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3.10 Estimation of ectopically expressed cyclin D1 protein: 
 Twenty four hours before transfection, HeLa cells were plated at a density of 2x106 cells 
per well in 10 cm dish for adherent cells. The cells then transiently transfected with 15µg of each 
of CCND1 full-YFP, CCND1-CDS-YFP using 50µl of Lipofectamine 2000 as per the 
manufacturer’s protocol. Similar transfection efficiencies were achieved. 24 hour post 
transfection the cells were harvested for CCND1 protein expression by western blotting described 
in section 3.6. Only YFP tagged cyclin D1 protein expression was analysed using polyclonal anti-
GFP antibody. 
 
3.11 Estimation of endogeneously expressed cyclin D1 protein: 
 Effect of miRNAs of miR-15/16 and miR-17-92 family on endogenous cyclin D1 was 
studied in MCF-7 and MDA-MB-453 breast cancer cell lines. These cell lines were transiently 
transfected with 15µg of each of miR-17-CMV and miR-15/16 constructs individually. 2x106 of 
MCF-7 and 5x106 of MDA-MB-453 cells were plated in 10cm dish for adherent cells one day 
prior to transfection. The next day the aforementioned constructs of miRNAs were transfected 
using 50µl of lipofectamine 2000 according to the manufacturer’s protocol. Mock transfections 
of Lipoectamine 2000 without miRNA constructs were also performed as a control. The cells 
were harvested after 48 hours of transfection for mRNA and protein expression analysis. Western 
blots were performed as described in section 3.6 using monoclonal mouse anti-human cyclin D1 
antibody. 
 
3.12 RNA isolation and cDNA synthesis: 
48 hour post transfection with miRNAs of miR-17-92 or miR-15/16 family, MCF-7 and 
MDA-MB-453 cells were harvested for RNA isolation. RNA isolation was performed using the 
RNeasy mini kit as per the manufacturer’s protocol. DNA was removed from RNA using the 
RNase-Free DNase Set during RNA isolation as per the given protocol. This DNA free RNA 
sample was used for cDNA synthesis. A 20µl reaction contains 4 µl of 5X buffer, 4 µl of MgCl2, 
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8 µl of deoxynucleoside triphosphate mix and 1 µl of random hexamer primer. To this, 1 µl of 
RNase inhibitor, 1 µl of Reverse transcriptase enzyme and 1 µl of DNA free RNA were added 
and RT-PCR was done using the following program: 
Temperature (oC) Time (minutes) 
25 10 
42 30 
99 5 
4 0.5 
4 90 
 
 
3.13 Real-time RT-PCR: 
cDNA prepared by reverse transcription was then used for cyclin D1 mRNA expression 
analysis by TaqmanTM real time quantitative polymerase chain reaction (RQ-PCR) method. 2 µl 
of cDNA was added to the 25 µl reaction containing 12.5 µl of 2X Absolute SYBR Green Rox 
mix, 2 µl of each primer and 6.5 µl of water and PCR was done on the ABI PRISM 7900 
Sequence Detection System (Applied Biosystems). The CCND1-RT-Fw and CCND1-RT-Rev 
primers were used to measure the relative expression of CCND1 mRNA in MCF-7 and MDA-
MB-453 cells. The CCND1 mRNA expression was normalized to TATA box binding protein 
(TBP) mRNA expression using the primer pair: TBP-RT-Fw and TBP-RT-Rev.  
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Results 
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4.1 Loss of 3’UTR leads to increased cyclin D1 expression: 
In order to identify whether the loss of the cyclin D1 3’UTR could contribute to the 
enhanced cyclin D1 protein expression observed in human malignancies, we transiently 
transfected HeLa cells with expression plasmids expressing the full length cyclin D1 cDNA 
(CCND1 full-YFP) or the cyclin D1 transcript without the 3’UTR (CCND1 CDS-YFP) 
(Fig.4.1a). These transcripts were tagged with YFP to enable tracking of transfected cells by 
fluorescence microscopy and for quantitative estimation of expression levels of the cyclin D1 
protein by flow cytometry.  
 
 
 
 
 
 
 
 
 
Fig.4.1a Different naturally occurring and patient specific forms of the cyclin D1 mRNA: The cyclin D1 
transcript is 4.5 kb with the 3’UTR spanning 3.1 kb. An approximately 467 nt AU-rich region in the 3’UTR 
harbours several signature ARE elements. In MCL as well as in some other cancers, genomic deletions of the 
3’UTR have been reported. In addition, point mutations that introduce premature polyadenylation, thereby 
truncating the UTR have been reported in MCL. Bioinformatic analysis of the long (3.1 kb) 3’UTR of cyclin 
D1 reveals potential microRNA binding sites for microRNAs. In contrast, the cancer associated isoforms of 
cyclin D1 with the shorter 3’UTR do not harbour these sites suggesting that they are not subject to regulation 
by these microRNAs. (Note: scale drawn in the figure is an approximation). 
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Interestingly, protein expression was significantly higher upon deletion of the cyclin D1 
3’UTR as assessed by fluorescence microscopy (Fig.4.1b) as well as quantitatively (2.13±0.057 
fold) using flow cytometry (n=3, P=0.01) (Fig.4.1d). This shows that the cylinD1 3’UTR is 
important for the regulation of cyclin D1 expression and the loss of this region could contribute 
to elevated levels of this protein.  
Cyclin D1-3´UTRCyclin D1+3´UTR
Fig.4.1b Increase in Cyclin D1 protein expression upon deletion of the 3’UTR: Fluorescence microscopic 
pictures of Hela cells transfected with cyclin D1-YFP with or without the 3’UTR. 
 
We also tested the levels of the cyclin D1 protein by Western blotting in these transiently 
transfected HeLa cells. Here also it could be seen that the levels of cyclin D1 protein were much 
higher in cells transfected with cyclin D1 without the 3’UTR confirming that the loss of this 
region can lead to cyclin D1 protein overexpression (Fig.4.1c).  
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Fig.4.1c: Cyclin D1 protein expression is increased in cells expressing cyclin D1 without the 3’UTR as 
compared to those expressing full length cyclin D1: Western blots of HeLa cells transfected with cyclin D1-
YFP with or without the 3’UTR. 
 
Since the loss of the cyclin D1 3’UTR can lead to elevated levels of cyclin D1, genomic 
deletions of this region which have been reported in different tumors could result in the observed 
cyclin D1 overexpression. In some patients however, instead of genomic deletions, mutations that 
introduce aberrant polyadenylation signals have been reported. We introduced two such patient 
specific mutations, described in MCL (Wiestner et al., 2007), specifically a point insertion of 
adenosine (A) between nucleotides number 308 and 309 after the stop codon of cyclin D1 or a 
deletion of trinucleotide sequence TCA at 309-311 of the 3’UTR in the expression construct with 
the full length cyclin D1 cDNA (Fig.4.1a). Indeed, upon introduction of these mutations cyclin 
D1 expression was significantly increased (1.33±0.051 fold in Ins308 and 1.31±0.046 fold in 
Δ309-311) compared to full length cyclin D1, (n=3, P=0.007 for Ins308 and P=0.009 for Δ309-
311). Although the increase in expression was statistically significant, the increase was much 
more marked in the 3’UTR contruct. These data showed that these mutations could contribute to 
cyclin D1 overexpression in these patients (Fig.4.1d). 
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Fig.4.1d Increase in Cyclin D1 protein expression with the different 3’UTR mutations. A bar graph of mean  
fluorescence intensity of YFP calculated by flow cytometry. CCND1 + 3´UTR Ins308 and CCND1 + 3´UTR Δ 
309-311 denote 3’UTR mutations observed in MCL patient samples. MFI: mean fluorescence intensity; * 
P<0.05 in each case.  
 
4.2 The cyclin D1 3’UTR can regulate chimeric reporter activity: 
Luciferase assays, due to a more accurate normalization of activity by the use of the dual 
luciferase reporter system, offer a more quantitative method for studying UTR mediated 
regulation (Chiu et al., 2005; Duan and Jefcoate, 2007). Therefore, and also in order to study the 
regulatory effect of the 3’UTR in isolation from the full length cyclin D1 mRNA, we fused the 
cyclin D1 3’UTR to a constitutively expressed luciferase reporter. Normalized luciferase activity 
was reduced to an average of 22.8 % in HeLa cells with the addition of the long CCND1 3’UTR 
as compared to luciferase only (Luc) (Fig.4.2a). This effect was cell line independent as similar 
results were obtained in different cell lines such as A549 and MCF-7(Fig.4.2b). These data 
confirm the role of the full length cyclin D1 3’UTR in the regulation of cyclin D1 and 
demonstrate that the 3’UTR can also regulate chimeric reporter expression. 
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Fig.4.2a The 3’UTR of cylinD1 can regulate chimeric reporter activity. Percent normalized luciferase activity 
of a constitutively expressed luciferase reporter with or without the 3’UTR are presented confirming the 
regulatory potential of this region in isolation from cyclin D1. Normalized luciferase activity without the 
3’UTR is considered 100 %. 
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Fig.4.2b Regulation of chimeric reporter gene by Cyclin D1 3’UTR is independent of the cell line.  The percent 
normalized luciferase activity is reduced to 15.82% and 32.92% in MCF-7 and A549 cell lines respectively. 
 
 
 56
                                                                                                                            R  e  s  u  l  t  s   
 
 
4.3 Effect of the 3’UTR deletion on cyclin D1 function: 
4.3.1 Effect on the proliferation of fibroblasts: 
 In order to check the effect of Cyclin D1 with and without 3’UTR on cell proliferation, 
NIH3T3 and IEC-18 cells were transduced with Cyclin D1constructs in the pMSCV-IRES-GFP 
vector (pMIG). GFP positive cells were checked for Cyclin D1 protein expression by western 
blotting using mouse anti-human cyclin D1 antibody. 
 Cell proliferation assays showed that the NIH3T3 cell line expressing CCND1 without the 
3’UTR showed a higher rate of proliferation (1.73 ± 0.64 fold after 8 days) (n=3, P≤0.038) 
compared to the cell lines with full 3’UTR (Fig.4.3a left panel). There was a remarkable 
difference in cell proliferation rate within the cell lines from day 4. The cells expressing CCND1 
without the 3’UTR proliferated more than the control cells expressing the empty pMIG vector. 
Thus, overexpression of cyclin D1 on account of 3’UTR deletions in mouse fibroblasts might 
have increased the rates of G0-S phase and G1-S phase transition leading to increased 
proliferation rate (Quelle et al., 1993). These data demonstrate that the proliferative activity of 
cyclin D1 is dependent on the presence of its 3’UTR suggesting that mutations in this region 
which might increase the cyclin D1 protein expression as observed in Fig.4.1d could contribute 
to malignancy. 
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Fig.4.3a Proliferation curves of NIH3T3 and IEC-18 expressing the cyclin D1 with or without 3’UTR or empty 
vector (pMIG). This is a representative of the three independent experiments of cell proliferation. Number of 
viable cells was determined after trypan blue exclusion. 
 
 The proliferation assay was also performed in the IEC-18, the rat epithelial cell line which 
normally does not express cyclin D1. We made IEC18 cell lines which stably expressed cyclin 
D1 with or without 3’UTR (Fig.4.3a right panel). The cell line expressing cyclin D1 without the 
3’UTR showed a higher proliferation rate (1.49 fold after 8 days) than the cells expressing 
CCND1 with 3’UTR or empty vector, similar to NIH3T3 cell lines. However, in the IEC18 cell 
lines, cells expressing CCND1 with the 3’UTR or empty vector transduced cells showed 
comparable rates of proliferation.  
4.3.2 Effects on cell cycle regulation: 
Since cyclin D1 is a G1 type of cyclin that plays an important role in cell cycle regulation 
it was interesting to study effect of the cyclin D1 3’UTR on cell cycle in IEC-18 cell line which 
does not express cyclin D1 endognously. IEC-18 cell lines were thus transduced with cyclin D1 
with or without 3’UTR or empty vector as discussed in methods section to stably express cyclin 
D1 and cell cycle analysis was performed. There was no change in percentage of cells in G1 and 
G2 phases of cell cycle in cells expressing CCND1 with 3’UTR or empty vector as compared to 
the untransduced control IEC-18 cells (Table 1). However cells expressing CCND1 without 
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3’UTR showed a significant reduction in percentage of cells in G1 phase and increase in 
percentage of cells in G2 phase.  
Type of cells G1 phase S phase G2 phase 
Conrol cells 
(untransduced) 
68 
 
26.75 
 5.26 
Empty vector control 67.14 24.26 8.61 
Cyclin D1 + 3’UTR 70.43  22.12 7.45 
Cyclin D1- 3’UTR 57.84  21.9 20.26 
Table 1 The above table indicates the percantage of cells in different phases of cell cycle in untransduced IEC-
18 cell line and stable cell lines expressing empty vector, cyclin D1 with or without 3’UTR. 
 
Increase in G2 phase demonstrates that the cells expressing cyclin D1 without the 3’UTR 
proliferate with shorter G1-S phase as compared to that with cells with cyclin D1 with 3’UTR or 
control cells (Fig.4.3b). The change in cell cycle pattern in IEC-18 cell stable cell lines confirms 
the cell proliferation data showing the potential role of the 3’UTR in cyclin D1 regulation.  
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G1phase:57,8%
G2 phase:20,26%
G1phase:70,43%
G2 phase:7,45%
G1phase:67,14%
G2 phase:8,61%
G1phase:68%
G2 phase:5,26%
 
Fig.4.3b Cell cycle analysis of IEC-18 cell lines. The upper panel indicates control cells on left and IEC-18 
with empty vector on right. The lower panel shows the IEC-18 cells with CCND1 with 3’UTR on left and 
CCND1 without 3’UTR on right. Two red peaks in the figure indicate the G1 (left) and the G2 phase (right) of 
cell cycle. This figure is representative of three independent experiments.  
 
Our data shows the regulatory potential of the cylin D1 UTR and its impact on cyclin D1 
expression and function. These data indicate the presence of elements in the 3’UTR of cyclin D1 
that regulate cyclin D1 expression and function.  
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4.4 Bioinformatic analysis of cyclin D1 3’UTR: 
Identification of ARE elements: 
 We scanned the 3’UTR for elements that could potentially regulate cyclin D1 
expression.  An analysis for the ARE sequences was performed by the University of California 
Santa Cruz Genome Browser May 2004 (hg17) assembly. We observed that the UTR contains 7 
reiterations of the signature ARE sequence AUUUA. 6 of these 7 motifs can be found in an 
approximately 474 nt AU-rich region between nucleotides 1369 and 1838 of the cyclin D1 
3’UTR.  
GGGCGCCAGGCAGGCGGGCGCCACCGCCACCCGCAGCGAGGGCGGAGCCGGCCCCAGGUGCUCCCCUGACAGUCCCUCCUCUCCGGAGCAUUUUGAU
ACCAGAAGGGAAAGCUUCAUUCUCCUUGUUGUUGGUUGUUUUUUCCUUUGCUCUUUCCCCCUUCCAUCUCUGACUUAAGCAAAAGAAAAAGAUUACC
CAAAAACUGUCUUUAAAAGAGAGAGAGAGAAAAAAAAAAUAGUAUUUGCAUAACCCUGAGCGGUGGGGGAGGAGGGUUGUGCUACAGAUGAUAGAGG
AUUUUAUACCCCAAUAAUCAACUCGUUUUUAUAUUAAUGUACUUGUUUCUCUGUUGUAAGAAUAGGCAUUAACACAAAGGAGGCGUCUCGGGAGAGG
AUUAGGUUCCAUCCUUUACGUGUUUAAAAAAAAGCAUAAAAACAUUUUAAAAACAUAGAAAAAUUCAGCAAACCAUUUUUAAAGUAGAAGAGGGUUU
UAGGUAGAAAAACAUAUUCUUGUGCUUUUCCUGAUAAAGCACAGCUGUAGUGGGGUUCUAGGCAUCUCUGUACUUUGCUUGCUCAUAUGCAUGUAGU
CACUUUAUAAGUCAUUGUAUGUUAUUAUAUUCCGUAGGUAGAUGUGUAACCUCUUCACCUUAUUCAUGGCUGAAGUCACCUCUUGGUUACAGUAGCG
UAGCGUGCCCGUGUGCAUGUCCUUUGCGCCUGUGACCACCACCCCAACAAACCAUCCAGUGACAAACCAUCCAGUGGAGGUUUGUCGGGCACCAGCC
AGCGUAGCAGGGUCGGGAAAGGCCACCUGUCCCACUCCUACGAUACGCUACUAUAAAGAGAAGACGAAAUAGUGACAUAAUAUAUUCUAUUUUUAUA
CUCUUCCUAUUUUUGUAGUGACCUGUUUAUGAGAUGCUGGUUUUCUACCCAACGGCCCUGCAGCCAGCUCACGUCCAGGUUCAACCCACAGCUACUU
GGUUUGUGUUCUUCUUCAUAUUCUAAAACCAUUCCAUUUCCAAGCACUUUCAGUCCAAUAGGUGUAGGAAAUAGCGCUGUUUUUGUUGUGUGUGCAG
GGAGGGCAGUUUUCUAAUGGAAUGGUUUGGGAAUAUCCAUGUACUUGUUUGCAAGCAGGACUUUGAGGCAAGUGUGGGCCACUGUGGUGGCAGUGGA
GGUGGGGUGUUUGGGAGGCUGCGUGCCAGUCAAGAAGAAAAAGGUUUGCAUUCUCACAUUGCCAGGAUGAUAAGUUCCUUUCCUUUUCUUUAAAGAA
GUUGAAGUUUAGGAAUCCUUUGGUGCCAACUGGUGUUUGAAAGUAGGGACCUCAGAGGUUUACCUAGAGAACAGGUGGUUUUUAAGGGUUAUCUUAG
AUGUUUCACACCGGAAGGUUUUUAAACACUAAAAUAUAUAAUUUAUAGUUAAGGCUAAAAAGUAUAUUUAUUGCAGAGGAUGUUCAUAAGGCCAGUA
UGAUUUAUAAAUGCAAUCUCCCCUUGAUUUAAACACACAGAUACACACACACACACACACACACACAAACCUUCUGCCUUUGAUGUUACAGAUUUAA
UACAGUUUAUUUUUAAAGAUAGAUCCUUUUAUAGGUGAGAAAAAAACAAUCUGGAAGAAAAAAACCACACAAAGACAUUGAUUCAGCCUGUUUGGCG
UUUCCCAGAGUCAUCUGAUUGGACAGGCAUGGGUGCAAGGAAAAUUAGGGUACUCAACCUAAGUUCGGUUCCGAUGAAUUCUUAUCCCCUGCCCCUU
CCUUUAAAAAACUUAGUGACAAAAUAGACAAUUUGCACAUCUUGGCUAUGUAAUUCUUGUAAUUUUUAUUUAGGAAGUGUUGAAGGGAGGUGGCAAG
AGUGUGGAGGCUGACGUGUGAGGGAGGACAGGCGGGAGGAGGUGUGAGGAGGAGGCUCCCGAGGGGAAGGGGCGGUGCCCACACCGGGGACAGGCCG
CAGCUCCAUUUUCUUAUUGCGCUGCUACCGUUGACUUCCAGGCACGGUUUGGAAAUAUUCACAUCGCUUCUGUGUAUCUCUUUCACAUUGUUUGCUG
CUAUUGGAGGAUCAGUUUUUUGUUUUACAAUGUCAUAUACUGCCAUGUACUAGUUUUAGUUUUCUCUUAGAACAUUGUAUUACAGAUGCCUUUUUUG
UAGUUUUUUUUUUUUUUAUGUGAUCAAUUUUGACUUAAUGUGAUUACUGCUCUAUUCCAAAAAGGUUGCUGUUUCACAAUACCUCAUGCUUCACUUA
GCCAUGGUGGACCCAGCGGGCAGGUUCUGCCUGCUUUGGCGGGCAGACACGCGGGCGCGAUCCCACACAGGCUGGCGGGGGCCGGCCCCGAGGCCGC
GUGCGUGAGAACCGCGCCGGUGUCCCCAGAGACCAGGCUGUGUCCCUCUUCUCUUCCCUGCGCCUGUGAUGCUGGGCACUUCAUCUGAUCGGGGGCG
UAGCAUCAUAGUAGUUUUUACAGCUGUGUUAUUCUUUGCGUGUAGCUAUGGAAGUUGCAUAAUUAUUAUUAUUAUUAUUAUAACAAGUGUGUCUUAC
GUGCCACCACGGCGUUGUACCUGUAGGACUCUCAUUCGGGAUGAUUGGAAUAGCUUCUGGAAUUUGUUCAAGUUUUGGGUAUGUUUAAUCUGUUAUG
UACUAGUGUUCUGUUUGUUAUUGUUUUGUUAAUUACACCAUAAUGCUAAUUUAAAGAGACUCCAAAUCUCAAUGAAGCCAGCUCACAGUGCUGUGUG
CCCCGGUCACCUAGCAAGCUGCCGAACCAAAAGAAUUUGCACCCCGCUGCGGGCCCACGUGGUUGGGGCCCUGCCCUGGCAGGGUCAUCCUGUGCUC
GGAGGCCAUCUCGGGCACAGGCCCACCCCGCCCCACCCCUCCAGAACACGGCUCACGCUUACCUCAACCAUCCUGGCUGCGGCGUCUGUCUGAACCA
CGCGGGGGCCUUGAGGGACGCUUUGUCUGUCGUGAUGGGGCAAGGGCACAAGUCCUGGAUGUUGUGUGUAUCGAGAGGCCAAAGGCUGGUGGCAAGU
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GCACGGGGCACAGCGGAGUCUGUCCUGUGACGCGCAAGUCUGAGGGUCUGGGCGGCGGGCGGCUGGGUCUGUGCAUUUCUGGUUGCACCGCGGCGCU
UCCCAGCACCAACAUGUAACCGGCAUGUUUCCAGCAGAAGACAAAAAGACAAACAUGAAAGUCUAGAAAUAAAACUGGUAAAACCCCA 
Fig.4.4a Identification of AU-rich elements in the cylin D1 3’UTR. AUUUA pentamers identified in the cyclin 
D1 3’UTR are highlighted in gray and the 474 nt. region deleted in the ΔARE-YFP constructs is underlined. 
In the Flu-7ΔARE construct, all AUUUA sites were mutated to ACUGA. 
 
Identification of potential microRNA binding sites: 
An analysis of the cyclin D1 3’UTR for putative microRNA binding sites was performed 
using microRNA prediction software mentioned in section 2.5. These results indicated that the 
3.1 kb cyclin D1 3’UTR is a potential target of several microRNAs. The miRNAs predicted to 
target cyclin D1 3’UTR include let-7 family members, miR-17-92 cluster, miR-1/206 and miR-
15/16 family members. All of these microRNAs are shown to have conserved binding sites 
across various species. The microRNAs themselves are conserved across species too. miR-15/16 
microRNAs are predicted to have two highly conserved binding sites at nucleotides position 
1961-1967 and 2034-2040  whereas miR-17-92 cluster miRNAs  have a conserved putative target 
site at nucleotide position 1014- 1020 (Fig.4.4b). Free energy values for miR-15/16 and miR-17 
cluster miRNAs are -21.5 and -19.5 respectively which show the high possibility of targeting the 
cyclin D1 3’UTR.  
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Fig.4.4b The microRNA binding sites in cyclin D1 3’UTR are highly conserved across species The cyclin D1 
3’UTR shows two highly conserved target sites (seven species) for miR-15/16 family at nucleotides position 
1961-1967 and 2034-2040 and one highly conserved (six species) site for miR-17/20a at position position 1014- 
1020. The conservation of the seed sequence of the microRNA and its complementary region across species is 
depicted (nucleotides highlighted in gray) and the minimum free energy values of miRNA-target interaction 
are included as ΔG values. Note: The figure is illustrative and not drawn to scale. 
 
Interestingly the ARE containing regions and the potential microRNA regulatory regions 
in the 3’UTR are non-overlapping (Fig.4.4c) indicating independent functions of these regions in 
cyclin D1 regulation. 
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Fig.4.4c Different non-overlapping potential regulatory regions in the cyclin D1 3’UTR: Analysis of the cyclin 
D1 3’UTR using different microRNA target prediction software shows several potential microRNA binding 
sites shown in vertical lines below the cyclin D1 3’UTR. The AU rich elements (AREs) which include several 
highly conserved AUUUA motifs are contained within an approximately 467 nt region in the UTR shown in a 
closed rectangle above the UTR. MicroRNA target regions using the TargetScan software (labelled T-ScanS 
miRNA) and PicTar software depicting microRNAs conserved in 4 or 5 species are labelled  as PicTar 4 
species and PicTar 5 species respectively. Each microRNA binding site is shown as a vertical line below the 
3’UTR. Cross species conservation is depicted at the bottom of the figure 
AREs
3‘UTR
 
4.5 The repressive function of the cyclin D1 3’UTR is independent 
of AREs: 
AREs in the cyclin D1 3’UTR have been previously reported, but a study of their 
contribution to cyclin D1 expression remained to be performed. It has been hypothesised that 
cyclin D1 AREs are responsible for its regulation and that the loss of these potentially 
destabilizing elements from the cyclin D1 UTR could contribute to the observed stable 
overexpression of cyclin D1 although this possibility has not yet been addressed experimentally. 
We therefore deleted a 474 nt region of the cyclin D1 3’UTR which includes 6 out of the 7 
AUUUA pentamers (nucleotides 1359 to 1832 of the 3’UTR) in the full-length cyclin D1 
(ΔARE-YFP) construct. Transfection of the ARE deletion construct, failed to show an increase in 
cyclin D1 expression. In contrast, there was a modest (0.77±0.08 fold, n=3) but significant 
reduction (P=0.038) of cyclin D1 protein expression measured by quantitative FACS analysis 
(Fig.4.5a) suggesting that the AREs might have a stabilizing function on cyclin D1 mRNA.  
 64
                                                                                                                            R  e  s  u  l  t  s   
 
 
CCND1 + 3´UTR 
Δ ARE
CCND1 + 3´UTR
*
0
10
20
30
40
50
60
70
80
M
FI
*
 
Fig.4.5a The mean fluorescence intensity of YFP expression using cylinD1-YFP with the full UTR is compared 
with the cyclin D1-YFP with the 3’UTR harbouring deletions of a 474 nt region which includes an AU rich 
element (ARE) region interspersed with 6 of the 7 AUUUA motifs present in the cyclin D1 3’UTR CCND1 + 
3´UTR ΔARE. MFI: mean fluorescence intensity; * P<0.05 
 
This is interesting because AREs in the cyclin D1 have been hypothesised to play a destabilizing 
role.  
Since the luciferase assay is much more sensitive in measuring the impact of these 
changes, we sought to assess the effects of ARE deletion on luciferase reporter activity. We 
therefore systematically mutated all seven AUUUA pentamers from the cyclin D1 3’UTR fused 
to a luciferase reporter to ‘ACUGA’. As we have mentioned previously, the addition of the 
3’UTR to the luciferase reported leads to a significant reduction in luciferase activity. If the ARE 
elements have a destabilizing effect on the cyclin D1 mRNA as has been hypothesised (Rimokh 
et al., 1994a; Wiestner et al., 2007), deletion of these signature ARE sequences should rescue the 
reduction in luciferase activity by the 3’UTR. In contrast, the luciferase activity is drastically 
reduced to 3.24 % ± 3.73 compared to that with the full length 3’UTR with intact ARE sequences 
(Fig.4.5b) in HeLa cells.  
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Fig.4.5b The normalized luciferase activity is reduced to 3.24% upon mutation of the 7 ARE sequences in the 
cyclin D1 3’UTR when compared to the full 3’UTR  
 
FACS analysis and luciferase reporter assay results together suggest that these AREs have 
a stabilizing effect on cyclin D1 transcripts similar to other recently reported AREs (Fialcowitz-
White et al., 2007).  It can be inferred from these data that the increased level of cyclin D1 
expression upon deletion of the 3’UTR is likely to be attributable to other regulatory elements. 
 
4.6 The 3’UTR of cyclin D1 is a target of microRNA mediated 
regulation: 
Other regulatory elements analysed are the predicted miRNAs that might target the cyclin 
D1 3’UTR and finetune the cyclin D1 protein expression. One of the most interesting of these 
microRNAs were microRNAs of the miR-15/16 family and the miR-17 cluster, both of which 
have been shown to be involved in lymphoid malignancies. Moreover, the miR15/16 microRNAs 
have been shown to regulate the expression of cell cycle regulatory genes. MicroRNAs of the 
miR-17 cluster are located in a region of DNA which is amplified in a number of human B cell-
lymphomas. Recently, the amplification of this cluster has also been demonstrated in a mantle 
cell lymphoma cell line (Rinaldi et al., 2007). Several putative microRNA targets have been 
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predicted by computational methods, with a very minor proportion being experimentally 
validated. 
4.6.1 Cyclin D1 is the direct target of miR-17 cluster miRNAs: 
We sought to determine whether miR-17 cluster miRNAs, which have been shown to be 
amplified in B cell lymphomas including MCL, target cyclin D1. The dual-luciferase reporter 
assay was employed to show the direct interaction between miR-17/20a miRNAs and the 3’UTR 
of Cyclin D1. First of all, the luciferase assay was performed to check the functionality of the 
miR-17-92 miRNAs cloned into the CMV-17-cluster construct in a cell line. The miR-17-5p and 
miR-20a sensor plasmids (see materials and methods) that contain two repeats of the perfect 
complementary sequence to the miR-17-5p and miR-20a binding sites respectively were co-
transfected with CMV-17-cluster into A549 cells. Similar transfections were performed with 
pGL3-Control (Luc) empty vector as a control. The normalised luciferase activity in percent with 
sensor plasmids was compared to that with the Luc vector.  
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Fig.4.6a The CMV-17-cluster is functional in Dual-Luciferase Assay System. The luciferase activity was 
normalized to Renilla luciferase and the normalized percent luciferase activities with sensor plasmids were 
compared to that with the Luc. The experiments are performed in triplicates and the ±S.E.M. values are 
shown in the graph. 
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 The luciferase activity significantly reduced to 12.52% and 23.14% with miR-17-5p and miR-
20a sensor plasmids respectively confirmed the functionality of the CMV-17-cluster construct. 
After the proof of functionality of CMV-17-cluster plasmid, the luciferase reporter assay was 
performed with the reg-17-92 and reg-17-92-M constructs (see materials and methods) in A549 
cells to show the direct interaction between 3’UTR::miR-17-5p/miR-20a.  
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Fig.4.6b Specific targeting of cyclin D1 by miR-17 cluster microRNAs. The normalised luciferase activity after 
transfection of the constitutively expressed luciferase plasmid is compared to the luc-reg-17/20a or the luc-
17/20a mut constructs. The activity of the luciferase without a 3’UTR is considered 100 %. The assay is 
performed in triplicates and ±S.E.M. values of three independent experiments are shown. 
 
We observed that the introduction of a region containing a highly conserved miR-17/20a binding 
site (reg-17-92) led to a significant reduction in the mean normalized luciferase activity by an 
average of 21.46%±5.44 in transfected cells upon co-transfection with 1.5µg of the CMV-miR-17 
cluster plasmid. This reduction was completely rescued by the mutation of the putative conserved 
‘seed’ sequence in the miRNA binding sites (reg-17-92-M) confirming that microRNAs of the 
miR-17 cluster play a role in the regulation of cyclin D1.  
4.6.2 MicroRNAs miR-15a and miR-16-1 specifically target the cyclin 
D1: 
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In order to directly test whether the cyclin D1 3’UTR is a direct target of the mir-15/16 
microRNAs, we cloned a small portion of the region containing putative miR-15/16 binding sites, 
reg-15/16 (see Materials and Methods) harbouring both the potential miR-15/16 binding sites was 
cloned downstream of Luc and used for the reporter assay. For the analysis of miR-15/16::cyclin 
D1 interaction, synthetic oligonucleotide mimics of microRNA precursors (Pre-miRs) for mir-16-
1 and miR-15a or a non-cognate microRNA control (miR-95) (see Materials and Methods) were 
transfected separately in addition to the reg-15/16 reporter construct into HeLa cells and their 
normalized luciferase activity was compared to the reg-15/16 reporter activity without 
exogeneously introduced microRNAs after 24 hours. Similar transfections were also performed 
with a construct (reg-15/16-M3) in which mutations were introduced in the region with perfect 
complementarity, termed the ‘seed’ sequence to determine the specificity of the interaction.  
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Fig.4.6c The cyclin D1 3’UTR is a target of miR-15/16 family microRNAs. The normalised luciferase activity 
after transfection of the luciferase plasmid in which a region containing the two miR-15/16 binding sites (luc-
reg-15/16) was cloned with or without the addition of miR-15a, miR-16-1 or miR-95 non-cognate microRNAs 
is shown on the left side of the panel. On the right side, luciferase activity using the same region with 
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mutations in the ‘seed’ sequence of these microRNA binding sites (reg-15/16) with or without externally added 
microRNAs is shown.  
 
As expected the normalized luciferase activity of reg-15/16 was reduced significantly by 
58.99%±6.12 and 66.73%±4.44 upon addition of miR-16-1 and miR-15a precursors respectively 
whereas the non-cognate control miR-95 did not show such a reduction, showing that the 
miR15/16 microRNAs specifically target the cyclin D1 3’UTR. Moreover, the reg-15/16-M3 
plasmid was insensitive to miR15/16 introduction confirming the specificity of the 
microRNA::target interaction (Fig.4.6c).  The dual-luciferase reporter assays demonstrated that 
the Cyclin D1 3’UTR is directly and specifically targeted by the microRNAs of miR-17 cluster 
and miR-15/16 family as both of these family members reduced the luciferase activity 
significantly. Even though the reduction with miR-17 microRNAs was significant, it was not as 
high as that with the miR-15/16 miRNAs, probably because there are two putative miR-15/16 
binding sites in reg-15/16 as opposed to a single miR-17/20a binding site in reg-17-92. These 
data show that the binding of these microRNAs play an important role in the repression of cyclin 
D1 mediated by the 3’UTR and that the abrogation of microRNA regulation by aberrant mutation 
or deletion of these regions could result in cyclin D1 overexpression observed in human tumors 
including MCL. 
4.6.3 Effect of miR-17-92 and miR15/16 miRNAs on endogenous cyclin 
D1: 
Although luciferase reporter assays demonstrate direct interactions of microRNAs with the 
cyclin D1, it is important to demonstrate the targeting of endogenous cyclin D1 by these 
microRNAs. Moreover, it is necessary to demonstrate that cyclin D1 expression is unaffected by 
these microRNAs in cells in which the cyclin D1 3’UTR has been deleted. Since cyclin D1 
overexpression is also common in breast cancer and since MCL cell lines are known to be 
difficult to transfect, we used the cyclin D1 overexpressing cell lines MCF-7 and MDA-MB-453. 
The MCF-7 cell line harbors an intact cyclin D1 gene whereas the MDA-MB-453 cell line 
harbors genomic deletions of the cyclin D1 3’UTR (Lebwohl et al., 1994). Upon transfection of 
these cell lines with vectors expressing the miR-17 cluster microRNAs (CMV-miR-17 cluster) or 
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the miR-15/16 family (a kind gift from Dr Patrick Lewis, Merck Co. Inc.), we observed that the 
levels of endogeneous cyclin D1 protein could be significantly downregulated in the MCF-7 cell 
line but not in the MDA-MB-453 cell line which has cyclin D1 3’UTR deletions (Fig.4.6d).  
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Fig.4.6d Western blots show the levels of endogenous cyclin D1 levels after mock trasnfections, no 
trasnfections or trasnfections with miR-17 cluster and miR15/16 microRNA expressing plasmids in MCF-7 
(Left panel) and MDA-MB453 (right panel) cell lines. This blot is representative of three independent 
experiments. Cyclin D1 protein expression is normalized to actin 
 
Significant decrease in cyclin D1 protein expression in MCF-7 cells indicated that externally 
introduced miR-17 cluster and miR-15/16 family miRNAs bind to the 3’UTR of cyclin D1 and 
negatively regulate the cyclin D1 mRNA. No change in cyclin D1 protein expression in MDA-
MB-453 cells demonstrated that loss of the 3’UTR could help cyclin D1 escape the repressive 
effect of the miRNAs. Thus, overexpression of cyclin D1 in many tumors might partly be due to 
its escape from the miRNA binding to its 3’UTR. Further mRNA expression analysis of cyclin 
D1 in both of these cell lines was performed and interestingly, in both cases, the levels of mRNA 
were unchanged, showing that these microRNAs mediate post-transcriptional regulation of cyclin 
D1 (Fig.4.6e). 
 71
                                                                                                                            R  e  s  u  l  t  s   
 
 
 72
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
Mock Untreated miR-17 miR-16
Fo
ld
 re
gu
la
tio
n
MCF-7
MDA-MB-453
 
Fig.4.6e Cyclin D1 mRNA expression by TaqmanTM real time RT-PCR. The graph indicates the mean of three 
independent experiments and ±S.E.M. values. Relative expression of cyclin D1 mRNA was normalized to the 
housekeeping TBP gene. 
 
Cyclin D1 mRNA expression was insignicantly lowered upon introduction of miR-17 
cluster miRNAs in MCF-7 cells whereas no change was observed with miR-15/16 miRNAs in 
both cell lines. These data show that the binding of these microRNAs play an important role in 
the repression of cyclin D1 mediated by the 3’UTR and that the abrogation of microRNA 
regulation by aberrant mutation or deletion of these regions render the cyclin D1 insensitive to 
microRNA mediated repression and account at least partially for cyclin D1 over-expression 
observed in human tumors. 
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Discussion 
 
 
Many human tumor cells escape normal regulation of cell cycle progression and growth 
either by overexpressing cyclin D1 or by inactivating proteins that regulate it or are necessary for 
its activity (Sherr, 1996). However, mutations in the coding region of cyclin D1 have not been 
reported. The most common alteration involving the cyclin D1 locus is the t (11;14) translocation 
which can be observed in virtually all cases of MCL. Although the juxtaposition of the cyclin D1 
gene to the IgH enhancer leads to the ectopic expression of cyclin D1 in MCL, this mechanism is 
thought to be insufficient for cyclin D1 overexpression, especially in the more proliferative tumor 
types. In addition, these hyperproliferative forms of MCL which are known to have a poor 
prognosis are associated with the expression of shorter cyclin D1 transcripts. These transcripts 
express a truncated form of the 3’UTR, which was believed to result from a normal alternative 
splicing event. In 2006, Wiestner et al., demonstrated that the shorter cyclin D1 transcripts derive 
from genomic mutations in the 3’UTR rather than from normal alternative splicing events 
(Wiestner et al., 2007). They observed that genomic deletions or point mutations that introduce 
premature polyadenylation signals lead to the truncation of this region in a number of MCL 
patients and cell lines. A systematic study of this region therefore was warranted to the 
pathogenesis of cyclin D1 deregulated tumors. 
The 3’ UTRs of eukaryotic mRNAs play important roles in post-transcriptional regulation 
by modulating transcript stability, translation efficiency, decay rate and subcellular localization 
(Mazumder et al., 2003). This region may therefore be viewed as a regulatory region that is 
important for the regulation of most genes. Interestingly, a recent study has shown that upon 
proliferation, several genes express truncated forms of their 3’UTRs by making use of proximal 
polyadenylation sites, thereby escaping 3’UTR mediated regulatory signals (Sandberg et al., 
2008). Given their important regulatory role, mutations that affect this region have been 
implicated in various diseases and their pathological role is becoming increasingly apparent 
(Conne et al., 2000). The 3’UTR of the cyclin D1 gene is approximately 3.1 kb long, which is 
more than 3 times longer than the average length (1.02 kb) of human 3’UTRs (Pesole et al., 
1997) suggesting a potential for 3’UTR mediated regulation of cyclin D1 expression. In this 
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dissertation, several regulatory elements were computationally identified in this region of the 
cyclin D1 gene. It is important to note that the disease specific forms of the cyclin D1 transcript 
described in MCL lack these potential regulatory regions. Moreover, earlier studies have 
described deletions of this region in breast cancer as well as in neuroblastoma. Since the cyclin 
D1 gene is also deregulated in solid tumors, especially in breast cancer, a screening of the cyclin 
D1 3’UTR for mutations in these tumors warrants investigation.  
Interestingly, given the crucial role of cyclin D1 in many different tumors, several studies 
have sought to establish cyclin D1 overexpression models. Although some studies have shown 
that cyclin D1 overexpression in fibroblasts has limited effects on cell growth and transformation, 
other reports demonstrated that cyclin D1 can transform fibroblasts (Asano et al., 1995; Jiang et 
al., 1993; Quelle et al., 1993). It has been hypothesized that these apparently contradictory results 
are due to the different expression levels of cyclin D1 in these various studies (Asano et al., 1995; 
Quelle et al., 1993). In our study, the expression of cyclin D1 in the NIH3T3 murine fibroblast 
cell line and in IEC-18 rat primary epithelial enterocytes, leads to an increase in proliferation, 
albeit only in cells transduced with 3’UTR deleted cyclin D1.  Therefore, our observation that the 
phenotypic consequence of cyclin D1 expression is different depending on the presence or 
absence of its 3’UTR is important and most probably of clinical relevance as it recapitulates the 
aforementioned study showing that states of proliferation of lymphocytes correlate with the 
expression of shortened 3’UTRs of several genes (Sandberg et al., 2008). It is important to note 
that in the natural setting, genes are normally flanked by several elements including 5 and 3’ 
UTRs. In this physiological scenario, the expression of that gene would have functional 
consequences that are different from those observed in the artificial cell line setting in which 
these elements (such as the 3’UTR) are excluded. Therefore, even though cyclin D1 is 
overexpressed in several tumors, malignant changes in these regulatory elements could 
substantially enhance its contribution to transformation. The relatively poor prognosis of MCL 
with high levels of truncated cyclin D1 transcripts supports this hypothesis (Sander et al., 2005).     
Since we observed that the expression of cyclin D1 increased significantly upon 
truncation of the 3’UTR, it is possible that the varied effects of cyclin D1 overexpression with or 
without the UTR are simply due to the differences in cyclin D1 protein expression.  This increase 
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in protein expression could result from the increased stability of cyclin D1 mRNA upon deletion 
of mRNA destabilizing elements from the 3’UTR. An important regulatory element in 3’UTRs of 
various mRNAs that affects their stability is the AU-rich element. A number of studies have 
hypothesized that AREs in the 3’UTR could potentially destabilize the cyclin D1 3’UTR and 
therefore their loss could contribute to enhanced stability and therefore overexpression of cyclin 
D1 protein. We found that mutations in the AUUUA sequences which are signature motifs of 
AREs, from the cyclin D1 3’UTR actually leads to a significant decrease in cyclin D1 protein 
levels and an almost complete loss of reporter activity suggesting that in contrast to previous 
hypotheses, AREs have a potentially stabilizing function on the cyclin D1 mRNA. Recently, 
several mRNAs have been shown to be stabilized by the binding of ARE binding proteins to the 
3’UTR  (Fialcowitz-White et al., 2007; Zhang et al., 2008; Zhao et al., 2008). The elucidation of 
such factors that bind to the cyclin D1 3’UTR could be interesting. However our results show 
also that 3’UTR mediated repression of cyclin D1 expression is not mediated by ARE elements 
but by other factors.  
MicroRNAs are small non-coding RNAs which can downregulate the expression of 
several mRNAs by binding to target sites in their 3’UTRs. They have been shown to act either as 
tumor suppressors by targeting the expression of oncogenes or as oncogenes by downregulating 
the expression of tumor suppressor genes (Calin and Croce, 2006). The role of these RNAs in 
cancer is now increasingly being appreciated (Esquela-Kerscher and Slack, 2006). We explored 
the possibility that microRNAs target the cyclin D1 3’UTR and identified potential microRNA 
binding sites in this region. Since microRNAs are known to fine tune the expression of their 
target mRNAs, the deregulation of microRNA mediated regulation could be an essential 
prerequisite for cellular transformation in cyclin D1 3’deleted cells. The acquisition of somatic 
mutations and deletions of this region could render these mRNAs immune to the control of 
microRNAs. A recently described example is the HMGA2 gene which is frequently mutated in 
several cancers. This gene was recently shown to harbour seven binding sites for microRNA of 
the let-7 family. In some tumors, the 3’UTR of this gene is deleted, thereby leading to HMGA2 
mRNA transcripts that are immune to regulation by let-7 and consequently, pathological 
overexpression of the HMGA2 gene (Mayr et al., 2007).  
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In our study, microRNAs of the miR-15/16 family and the miR-17/92 cluster were shown 
to directly target the cyclin D1 3’UTR and reduce the levels of cyclin D1 protein expression. The 
genomic amplification of the miR-17-92 cluster has been reported in MCL (Rinaldi et al., 2007). 
Accordingly, the loss of the binding site of this miRNA from the cyclin D1 gene would promote 
the constitutive over-expression of this proto-oncogene.  
MicroRNAs of the miR-15/16 family have also been implicated in CLLs (Calin et al., 
2002) and in recent studies, they have been shown to downregulate several transcripts which 
regulate cell cycle progression (Linsley et al., 2007). Interestingly we observe that a number of 
G1 cyclins including CCND2, CCND3, CCNE1 harbour predicted miR-15/16 binding sites. 
Therefore, it is conceivable that the rapid and efficient turnover of these cyclins, which is a 
prerequisite for cell cycle progression, could be co-ordinately regulated by these microRNAs. 
Our demonstration of microRNA targeting of the cyclin D1 transcripts confirms recent reports 
showing microRNA mediated regulation of cyclin D1 in MCL and breast cancer (Chen et al., 
2008; Yu et al., 2008). Importantly, our data also show that these microRNAs can regulate 
endogenous cyclin D1 levels in breast cancer cells with an intact 3’UTR but not in 3’UTR 
deleted cells. This study highlights the important contribution of the cyclin D1 3’UTR in its 
regulation, the deletion of which could be an important prerequisite for malignant transformation 
in MCL and solid tumors.  
In cancer, there is growing evidence pointing to the role of genomic deletions or 
premature truncations of the 3’UTR regions of proto-oncogenes (Mayr et al., 2007) which could 
eliminate microRNA binding sites in the target mRNA, thereby escaping microRNA mediated 
repression. This mechanism presents an additional and hitherto underappreciated regulation of 
proto-oncogenes in cancer.   
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Summary 
 
 
Deregulation of the cell cycle regulator cyclin D1 in a wide variety of tumors has 
highlighted the role of cell cycle alterations in cancer. Genomic amplifications, mutations or 
balanced chromosomal translocations involving this gene are believed to lead to its aberrant 
overexpression in tumors. Somatic mutations in the 3’UTR of cyclin D1 gene have been reported 
in breast cancer, neuroblastoma and mantle cell lymphoma patients although their contribution to 
the cyclin D1 deregulation is unclear. In our study, we confirmed a regulatory role of the 3’UTR 
in cyclin D1 expression. Our results demonstrated that deletion of the cyclin D1 3’UTR 
significantly alters cyclin D1 protein expression and function. Similarly, the introduction of 
mutations observed in MCL patients in the cyclin D1 3’UTR significantly increased the 
expression of the cyclin D1 protein. These results underline that in malignancies such as MCL, 
truncation of the 3’UTR due to genomic deletions or somatic mutations is a likely cause of cyclin 
D1 overexpression.  
In order to ascertain whether the deletion of the cyclin D1 3’UTR could impart 
proliferative properties to cells, thereby contributing to transformation, we assessed the 
phenotype of fibroblasts retrovirally transduced with cyclin D1 with or without the 3’UTR. 
Interestingly our results demonstrated marked changes in cyclin D1 function upon deletion of the 
cyclin D1 3’UTR. Cells expressing cyclin D1 without the 3’UTR proliferated significantly more 
than those expressing the full length cyclin D1. Similar results were observed in rat ileum 
epithelial cells which lack the endogenous cyclin D1. Thus our data confirm that the deletion of 
the 3’UTR confers a proliferative advantage to cells.  
Furthermore, in this dissertation, we focused on the different potential regulatory elements 
of the cyclin D1 3’UTR to assess their role in controlling cyclin D1 expression. We reasoned that 
elements in the 3’UTR that are responsible for the controlled expression of the cyclin D1 protein 
are lost in 3’UTR deleted tumors. Therefore, it would be interesting to specifically pinpoint the 
role of these elements and highlight their contribution to cyclin D1 protein expression. It is 
assumed that since AU-rich elements (AREs) in the 3’UTR of cyclin D1 could have a potential 
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destabilizing effect on the cyclin D1 mRNA, their loss could contribute to the observed 
overexpression of cyclin D1. Importantly, using highly sensitive reporter assays, we showed that 
the targeted loss of AREs from an otherwise intact 3’UTR leads to a decrease in reporter 
expression. These results demonstrate that the loss of these cis-acting elements in 3’UTR deleted 
tumors cannot account for cyclin D1 overexpression and there must be additional factors 
involved.  Using bioinformatic analysis, we identified putative binding sites for microRNAs, 
small regulatory non-coding RNAs that have been shown to have important roles in cancer. Our 
study confirmed that microRNAs of the miR-15/16 family and the miR-17-92 cluster directly 
target the cyclin D1 gene through post-transcriptional regulation. These microRNAs have been 
shown to be involved in a cell cycle regulation and in a number of malignancies, especially in B-
cell lymphoma. The various forms of cyclin D1 generated by deletions or mutations in the 
3”UTR of cyclin D1 in tumors exclude these microRNA binding sites. 
Taken together, our results demonstrate a regulatory role for the 3’UTR in cyclin D1 
expression and function. We show that the deletion of the cyclin D1 3’UTR leads to cyclin D1 
overexpression and confers a proliferative advantage to cells. Finally, our results characterize the 
regulators functions of the different cis and trans-acting elements of the cyclin D1 3’UTR and 
identify this region as a bona fide target of cell cycle regulatory microRNAs. Extending these 
findings to other oncogenes, it is conceivable that the escape of 3’UTR mediated regulation by 
the acquisition of additional mutations of this region is an under-appreciated mechanism in the 
pathogenesis of cancer. 
 
 
 
 
                                                                                   Z  u  s  a  m  m  e  n  f  a  s  s  u  n  g  
 
 
 
Zusammenfassung 
 
 
 Die Deregulierung des Zellzyklus-Regulators Cyclin D1 in einer Vielzahl verschiedener 
Tumorerkrankungen unterstreicht die Bedeutung von Zellzyklus-Veränderungen in 
Krebserkrankungen. Es wird angenommen, dass genomische Amplifikationen, Mutationen oder 
auch balancierte chromosomale Translokationen dieses Gens zu seiner aberranten 
Überexpression in den Tumoren führen. Daneben wurde auch somatische Mutationen der 3’UTR 
des Cyclin D1-Gens bei Mamakarzinom-, Neuroblastom- und MCL- Patienten berichtet, deren 
Beitrag zur Cyclin D1-Deregulierung noch unklar  war.  In dieser Studie konnten wir die 
regulatorische Rolle der 3’UTR bei der Cyclin D1-Expression bestätigen. So zeigen unsere 
Ergebnisse, dass eine Deletion der Cyclin D1-3’UTR die Expression und Funktion dieses 
Proteins signifikant verändert. Genauso konnten wir zeigen, dass die in MCL-Patienten 
beobachteten Mutationen in den Cyclin D1-3’UTR die Expression des Cyclin D1-Proteins 
signifikant steigerte. Diese Ergebnisse unterstreichen, dass in der Erkrankung des MCL eine 
Verkürzung des 3’UTR durch genomische Deletionen oder somatische Mutationen der Cyclin 
D1-Überexpression wahrscheinlich zugrunde liegt. 
 Um festzustellen, ob die Deletion der Cyclin D1-3’UTR den betroffenen Zellen eine 
proliferative Vorteil verschafft und so zur Transformation beiträgt, untersuchten wir den 
Phänotyp von retroviral mit Cyclin D1 (mit oder ohne 3’UTR) transduzierten Fibroblasten. 
Interessanterweise zeigten unsere Ergebnisse deutliche Veränderungen der Cyclin D1-Funktion 
nach Deletion der Cyclin D1-3’UTR.  Zellen, die Cyclin D1 ohne 3’UTR exprimierten, 
proliferierten signifikant stärker als solche mit der vollen, Cyclin D1-Genexpression. 
Vergleichbare Resultate wurden mit Ileum-Epithelzellen der Ratte erzielt, die kein endogenes 
Cyclin D1 besitzen. Daher bestätigen unsere Ergebnisse, dass die Deletion des Cyclin D1-3’UTR  
Zellen zu einem proliferativen Vorteil der betroffenen Zelle führt. 
 Darüber hinaus untersuchten wir in dieser Dissertation die verschiedenen potentiellen 
regulatorischen Elemente der Cyclin D1-3’UTR um deren Rolle in der Regulation der Cyclin D1-
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Expression zu beurteilen. Dabei gingen wir von der Hypothese aus, dass die Elemente der 
3’UTR, die für die Kontrolle der Cyclin D1-Expression verantwortlich sind, in 3’UTR-deletierten 
Tumoren verloren gehen. Daher ist es von speziellem Interesse, die Rolle dieser Elemente und 
ihren Auswirkung auf die Cyclin D1-Proteinexpression zu untersuchen. Es wird angenommen, 
dass der Verlust von AU-reiche Elemente (AREs) in der 3’UTR einen potentiell 
destabilisierenden Effekt auf die Cyclin D1 mRNA besitzen und ihr Verlust somit zur 
Überexpression des Cyclin D1-Proteins führt. Durch den Einsatz hochsensitiver Reporter-Assays 
konnten wir zeigen, dass der spezifische Verlust der AREs in einem ansonsten intakten 3’UTR zu 
einer Verringerung der Reporterexpression führt. Diese Resultate unterstreichen, dass der Verlust 
dieser cis-aktiven Elemente der 3’-UTR in Tumoren mit 3’UTR-Deletionen nicht für die Cyclin 
D1 Überexpression verantwortlich ist sondern zusätzliche Faktoren beteiligt sein müssen. Durch 
bioinformatische Analyse identifizierten wir mögliche Bindungsstellen für microRNAs, d.h. 
kleine regulatorische nicht-kodierende RNAs, die eine bedeutende Rolle in Krebserkrankungen 
spielen. Unsere Untersuchungen bestätigten, dass microRNAs der miR-15/16-Familie sowie des 
miR-17-92 –Cluster die Expression des Cyclin D1-Gens durch post-transkriptionelle Regulierung 
direkt beeinflussen. Es ist bekannt, dass diese microRNAs an der Zellzyklus-Regulierung sowie 
bei einer Reihe maligner Erkrankungen, insbesondere bei B-Zell-Lymphomen beteiligt sind. Den 
verschiedenen Cyclin D1-mRNAs mit Deletionen oder Mutationen der 3’UTR in Tumoren 
entstehen, fehlen diese microRNA-Bindungsstellen. 
 Zusammengefasst bestätigen unsere Ergebnisse die regulatorische Rolle der 3’UTR bei 
der Cyclin D1-Expression und –Funktion. Wir konnten zeigen, dass die Deletion der Cyclin D1 
3’UTR zu einer Cyclin D1-Überexpression führt und zu einem proliferativen Vorteil der 
betroffenen Zelle führt. Schließlich charakterisieren unsere Ergebnisse die regulatorischen 
Eigenschaften der verschiedenen cis- und trans-aktiven Elemente der Cyclin D1 3’UTR und 
identifizieren diese Region als eine bona fide Zielregion der Zellzyklus-regulatorischen 
microRNAs. Überträgt man diese Resultate auf andere Onkogene ist es denkbar, dass der Verlust 
der 3’UTR-vermittelten Gen-Regulation durch zusätzliche Mutationen dieser Region einen 
unterschätzten Mechanismus in der Pathogenese von Krebserkrankungen darstellt.    
 
 80
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
 81
References 
 
 
Akashi, M., Shaw, G., Hachiya, M., Elstner, E., Suzuki, G., and Koeffler, P. (1994). Number and  
location of AUUUA motifs: role in regulating transiently expressed RNAs. Blood 83, 
3182-3187. 
Asano, K., Sakamoto, H., Sasaki, H., Ochiya, T., Yoshida, T., Ohishi, Y., Machida, T., Kakizoe, 
T., Sugimura, T., and Terada, M. (1995). Tumorigenicity and gene amplification 
potentials of cyclin D1-overexpressing NIH3T3 cells. Biochem Biophys Res Commun 
217, 1169-1176. 
Atwater, J.A., Wisdom, R., and Verma, I.M. (1990). Regulated mRNA stability. Annu Rev Genet 
24, 519-541. 
Banks, P.M., Chan, J., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Gatter, K., Grogan, T.M., 
Harris, N.L., Isaacson, P.G., Jaffe, E.S., et al. (1992). Mantle cell lymphoma. A proposal 
for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16, 
637-640. 
Betticher, D.C., Thatcher, N., Altermatt, H.J., Hoban, P., Ryder, W.D., and Heighway, J. (1995). 
Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011. 
Bienvenu, F., Gascan, H., and Coqueret, O. (2001). Cyclin D1 represses STAT3 activation 
through a Cdk4-independent mechanism. J Biol Chem 276, 16840-16847. 
Blackshear, P.J. (2002). Tristetraprolin and other CCCH tandem zinc-finger proteins in the 
regulation of mRNA turnover. Biochem Soc Trans 30, 945-952. 
Boehm, T., and Rabbitts, T.H. (1989). The human T cell receptor genes are targets for 
chromosomal abnormalities in T cell tumors. FASEB J 3, 2344-2359. 
Bohnsack, M.T., Czaplinski, K., and Gorlich, D. (2004). Exportin 5 is a RanGTP-dependent 
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185-191. 
Buckley, M.F., Sweeney, K.J., Hamilton, J.A., Sini, R.L., Manning, D.L., Nicholson, R.I., 
deFazio, A., Watts, C.K., Musgrove, E.A., and Sutherland, R.L. (1993). Expression and 
amplification of cyclin genes in human breast cancer. Oncogene 8, 2127-2133. 
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Calin, G.A., and Croce, C.M. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6, 
857-866. 
Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., 
Keating, M., Rai, K., et al. (2002). Frequent deletions and down-regulation of micro- 
RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad 
Sci U S A 99, 15524-15529. 
Calin, G.A., Liu, C.G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C.D., Shimizu, M., 
Cimmino, A., Zupo, S., Dono, M., et al. (2004a). MicroRNA profiling reveals distinct 
signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101, 
11755-11760. 
Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., 
Rattan, S., Bullrich, F., Negrini, M., et al. (2004b). Human microRNA genes are 
frequently located at fragile sites and genomic regions involved in cancers. Proc Natl 
Acad Sci U S A 101, 2999-3004. 
Callender, T., el-Naggar, A.K., Lee, M.S., Frankenthaler, R., Luna, M.A., and Batsakis, J.G. 
(1994). PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck 
squamous cell carcinoma. Cancer 74, 152-158. 
Camacho, E., Hernandez, L., Hernandez, S., Tort, F., Bellosillo, B., Bea, S., Bosch, F., 
Montserrat, E., Cardesa, A., Fernandez, P.L., et al. (2002). ATM gene inactivation in 
mantle cell lymphoma mainly occurs by truncating mutations and missense mutations 
involving the phosphatidylinositol-3 kinase domain and is associated with increasing 
numbers of chromosomal imbalances. Blood 99, 238-244. 
Carballo, E., Lai, W.S., and Blackshear, P.J. (2000). Evidence that tristetraprolin is a 
physiological regulator of granulocyte-macrophage colony-stimulating factor messenger 
RNA deadenylation and stability. Blood 95, 1891-1899. 
Carmell, M.A., Xuan, Z., Zhang, M.Q., and Hannon, G.J. (2002). The Argonaute family: 
tentacles that reach into RNAi, developmental control, stem cell maintenance, and 
tumorigenesis. Genes Dev 16, 2733-2742. 
Chalfie, M., Horvitz, H.R., and Sulston, J.E. (1981). Mutations that lead to reiterations in the cell 
lineages of C. elegans. Cell 24, 59-69. 
 82
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Chan, J.A., Krichevsky, A.M., and Kosik, K.S. (2005). MicroRNA-21 is an antiapoptotic factor 
in human glioblastoma cells. Cancer Res 65, 6029-6033. 
Chang, T.C., and Mendell, J.T. (2007). microRNAs in vertebrate physiology and human disease. 
Annu Rev Genomics Hum Genet 8, 215-239. 
Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., 
Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., et al. (2007). 
Transactivation of miR-34a by p53 broadly influences gene expression and promotes 
apoptosis. Mol Cell 26, 745-752. 
Chen, C.Y., Chen, T.M., and Shyu, A.B. (1994). Interplay of two functionally and structurally 
distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function. 
Mol Cell Biol 14, 416-426. 
Chen, C.Y., Gherzi, R., Ong, S.E., Chan, E.L., Raijmakers, R., Pruijn, G.J., Stoecklin, G., 
Moroni, C., Mann, M., and Karin, M. (2001). AU binding proteins recruit the exosome to 
degrade ARE-containing mRNAs. Cell 107, 451-464. 
Chen, C.Y., and Shyu, A.B. (1994). Selective degradation of early-response-gene mRNAs: 
functional analyses of sequence features of the AU-rich elements. Mol Cell Biol 14, 8471-
8482. 
Chen, C.Y., and Shyu, A.B. (1995). AU-rich elements: characterization and importance in 
mRNA degradation. Trends Biochem Sci 20, 465-470. 
Chen, R.W., Bemis, L.T., Amato, C.M., Myint, H., Tran, H., Birks, D.K., Eckhardt, S.G., and 
Robinson, W.A. (2008). Truncation in CCND1 mRNA alters miR-16-1 regulation in 
mantle cell lymphoma. Blood 112, 822-829. 
Chiu, W.W., Kinney, R.M., and Dreher, T.W. (2005). Control of translation by the 5'- and 3'-
terminal regions of the dengue virus genome. J Virol 79, 8303-8315. 
Chowdhury, B., Krishnan, S., Tsokos, C.G., Robertson, J.W., Fisher, C.U., Nambiar, M.P., and 
Tsokos, G.C. (2006). Stability and translation of TCR zeta mRNA are regulated by the 
adenosine-uridine-rich elements in splice-deleted 3' untranslated region of zeta-chain. J 
Immunol 177, 8248-8257. 
Cleary, M.L. (1991). Oncogenic conversion of transcription factors by chromosomal 
translocations. Cell 66, 619-622. 
 83
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Conne, B., Stutz, A., and Vassalli, J.D. (2000). The 3' untranslated region of messenger RNA: A 
molecular 'hotspot' for pathology? Nat Med 6, 637-641. 
Coqueret, O. (2002). Linking cyclins to transcriptional control. Gene 299, 35-55. 
Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., and Croce, C.M. 
(2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in 
E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 103, 7024-7029. 
David, P.S., Tanveer, R., and Port, J.D. (2007). FRET-detectable interactions between the ARE 
binding proteins, HuR and p37AUF1. RNA 13, 1453-1468. 
Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F., and Hannon, G.J. (2004). Processing of 
primary microRNAs by the Microprocessor complex. Nature 432, 231-235. 
Dong, J.T., Boyd, J.C., and Frierson, H.F., Jr. (2001). Loss of heterozygosity at 13q14 and 13q21 
in high grade, high stage prostate cancer. Prostate 49, 166-171. 
Duan, H., and Jefcoate, C.R. (2007). The predominant cAMP-stimulated 3 x 5 kb StAR mRNA 
contains specific sequence elements in the extended 3'UTR that confer high basal 
instability. J Mol Endocrinol 38, 159-179. 
Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., Lund, E., and Dahlberg, J.E. 
(2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl 
Acad Sci U S A 102, 3627-3632. 
Elbashir, S.M., Lendeckel, W., and Tuschl, T. (2001). RNA interference is mediated by 21- and 
22-nucleotide RNAs. Genes Dev 15, 188-200. 
Esquela-Kerscher, A., and Slack, F.J. (2006). Oncomirs - microRNAs with a role in cancer. Nat 
Rev Cancer 6, 259-269. 
Ewen, M.E., and Lamb, J. (2004). The activities of cyclin D1 that drive tumorigenesis. Trends 
Mol Med 10, 158-162. 
Fantl, V., Stamp, G., Andrews, A., Rosewell, I., and Dickson, C. (1995). Mice lacking cyclin D1 
are small and show defects in eye and mammary gland development. Genes Dev 9, 2364-
2372. 
Fialcowitz-White, E.J., Brewer, B.Y., Ballin, J.D., Willis, C.D., Toth, E.A., and Wilson, G.M. 
(2007). Specific protein domains mediate cooperative assembly of HuR oligomers on AU-
rich mRNA-destabilizing sequences. J Biol Chem 282, 20948-20959. 
 84
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Frevel, M.A., Bakheet, T., Silva, A.M., Hissong, J.G., Khabar, K.S., and Williams, B.R. (2003). 
p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA 
stability of AU-rich element-containing transcripts. Mol Cell Biol 23, 425-436. 
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C.C., Burchard, J., Linsley, P.S., and Krichevsky, 
A.M. (2008). MicroRNA 21 promotes glioma invasion by targeting matrix 
metalloproteinase regulators. Mol Cell Biol 28, 5369-5380. 
Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G.V., Ciafre, S.A., and Farace, 
M.G. (2007). miR-221 and miR-222 expression affects the proliferation potential of 
human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282, 23716-
23724. 
Gillies, J.K., and Lorimer, I.A. (2007). Regulation of p27Kip1 by miRNA 221/222 in 
glioblastoma. Cell Cycle 6, 2005-2009. 
Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., and 
Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs. 
Nature 432, 235-240. 
Haritunians, T., Mori, A., O'Kelly, J., Luong, Q.T., Giles, F.J., and Koeffler, H.P. (2007). 
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with 
other agents in mantle cell lymphoma. Leukemia 21, 333-339. 
Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., Yatabe, Y., 
Kawahara, K., Sekido, Y., and Takahashi, T. (2005). A polycistronic microRNA cluster, 
miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. 
Cancer Res 65, 9628-9632. 
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G.A., Liu, C.G., 
Franssila, K., Suster, S., et al. (2005a). The role of microRNA genes in papillary thyroid 
carcinoma. Proc Natl Acad Sci U S A 102, 19075-19080. 
He, L., Thomson, J.M., Hemann, M.T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., 
Cordon-Cardo, C., Lowe, S.W., Hannon, G.J., et al. (2005b). A microRNA polycistron as 
a potential human oncogene. Nature 435, 828-833. 
Hernandez, L., Bea, S., Pinyol, M., Ott, G., Katzenberger, T., Rosenwald, A., Bosch, F., Lopez-
Guillermo, A., Delabie, J., Colomer, D., et al. (2005). CDK4 and MDM2 gene alterations 
 85
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type 
INK4a/ARF locus. Cancer Res 65, 2199-2206. 
Hiddemann, W., and Dreyling, M. (2003). Mantle cell lymphoma: therapeutic strategies are 
different from CLL. Curr Treat Options Oncol 4, 219-226. 
Holley, S.L., Heighway, J., and Hoban, P.R. (2005). Induced expression of human CCND1 
alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional 
differences. Int J Cancer 114, 364-370. 
Hosokawa, Y., and Arnold, A. (1998). Mechanism of cyclin D1 (CCND1, PRAD1) 
overexpression in human cancer cells: analysis of allele-specific expression. Genes 
Chromosomes Cancer 22, 66-71. 
Huang, S., Chen, C.S., and Ingber, D.E. (1998). Control of cyclin D1, p27(Kip1), and cell cycle 
progression in human capillary endothelial cells by cell shape and cytoskeletal tension. 
Mol Biol Cell 9, 3179-3193. 
Hutvagner, G., and Zamore, P.D. (2002). A microRNA in a multiple-turnover RNAi enzyme 
complex. Science 297, 2056-2060. 
Jacks, T., and Weinberg, R.A. (1998). The expanding role of cell cycle regulators. Science 280, 
1035-1036. 
Jares, P., Campo, E., Pinyol, M., Bosch, F., Miquel, R., Fernandez, P.L., Sanchez-Beato, M., 
Soler, F., Perez-Losada, A., Nayach, I., et al. (1996). Expression of retinoblastoma gene 
product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) 
mRNA levels and proliferative activity. Am J Pathol 148, 1591-1600. 
Jares, P., Colomer, D., and Campo, E. (2007). Genetic and molecular pathogenesis of mantle cell 
lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 7, 750-762. 
Jiang, W., Kahn, S.M., Zhou, P., Zhang, Y.J., Cacace, A.M., Infante, A.S., Doi, S., Santella, 
R.M., and Weinstein, I.B. (1993). Overexpression of cyclin D1 in rat fibroblasts causes 
abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8, 
3447-3457. 
Jing, Q., Huang, S., Guth, S., Zarubin, T., Motoyama, A., Chen, J., Di Padova, F., Lin, S.C., 
Gram, H., and Han, J. (2005). Involvement of microRNA in AU-rich element-mediated 
mRNA instability. Cell 120, 623-634. 
 86
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., 
Reinert, K.L., Brown, D., and Slack, F.J. (2005). RAS is regulated by the let-7 microRNA 
family. Cell 120, 635-647. 
Jones, T.R., and Cole, M.D. (1987). Rapid cytoplasmic turnover of c-myc mRNA: requirement of 
the 3' untranslated sequences. Mol Cell Biol 7, 4513-4521. 
Kakizuka, A., Miller, W.H., Jr., Umesono, K., Warrell, R.P., Jr., Frankel, S.R., Murty, V.V., 
Dmitrovsky, E., and Evans, R.M. (1991). Chromosomal translocation t(15;17) in human 
acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, 
PML. Cell 66, 663-674. 
Kane, R.C., Dagher, R., Farrell, A., Ko, C.W., Sridhara, R., Justice, R., and Pazdur, R. (2007). 
Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13, 5291-5294. 
Kent, O.A., and Mendell, J.T. (2006). A small piece in the cancer puzzle: microRNAs as tumor 
suppressors and oncogenes. Oncogene 25, 6188-6196. 
Khabar, K.S. (2005). The AU-rich transcriptome: more than interferons and cytokines, and its 
role in disease. J Interferon Cytokine Res 25, 1-10. 
Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and miRNAs exhibit 
strand bias. Cell 115, 209-216. 
Kim, V.N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell 
Biol 6, 376-385. 
Knudsen, K.E., Cavenee, W.K., and Arden, K.C. (1999). D-type cyclins complex with the 
androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59, 
2297-2301. 
Korsmeyer, S.J. (1992). Chromosomal translocations in lymphoid malignancies reveal novel 
proto-oncogenes. Annu Rev Immunol 10, 785-807. 
Krieger, S., Gauduchon, J., Roussel, M., Troussard, X., and Sola, B. (2006). Relevance of cyclin 
D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and 
mantle cell lymphoma. BMC Cancer 6, 238. 
Laroia, G., Cuesta, R., Brewer, G., and Schneider, R.J. (1999). Control of mRNA decay by heat 
shock-ubiquitin-proteasome pathway. Science 284, 499-502. 
 87
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Le Sage, C., Nagel, R., Egan, D.A., Schrier, M., Mesman, E., Mangiola, A., Anile, C., Maira, G., 
Mercatelli, N., Ciafre, S.A., et al. (2007). Regulation of the p27(Kip1) tumor suppressor 
by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26, 3699-3708. 
Lebwohl, D.E., Muise-Helmericks, R., Sepp-Lorenzino, L., Serve, S., Timaul, M., Bol, R., 
Borgen, P., and Rosen, N. (1994). A truncated cyclin D1 gene encodes a stable mRNA in 
a human breast cancer cell line. Oncogene 9, 1925-1929. 
Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854. 
Lee, Y., Jeon, K., Lee, J.T., Kim, S., and Kim, V.N. (2002). MicroRNA maturation: stepwise 
processing and subcellular localization. EMBO J 21, 4663-4670. 
Leveque, C., Marsaud, V., Renoir, J.M., and Sola, B. (2007). Alternative cyclin D1 forms a and b 
have different biological functions in the cell cycle of B lymphocytes. Exp Cell Res 313, 
2719-2729. 
Linsley, P.S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M.M., Bartz, S.R., Johnson, J.M., 
Cummins, J.M., Raymond, C.K., Dai, H., et al. (2007). Transcripts targeted by the 
microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27, 
2240-2252. 
Liu, J., Carmell, M.A., Rivas, F.V., Marsden, C.G., Thomson, J.M., Song, J.J., Hammond, S.M., 
Joshua-Tor, L., and Hannon, G.J. (2004). Argonaute2 is the catalytic engine of 
mammalian RNAi. Science 305, 1437-1441. 
Liu, Q., Fu, H., Sun, F., Zhang, H., Tie, Y., Zhu, J., Xing, R., Sun, Z., and Zheng, X. (2008). 
miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic 
Acids Res 36, 5391-5404. 
Look, A.T. (1997). Oncogenic transcription factors in the human acute leukemias. Science 278, 
1059-1064. 
Lu, F., Gladden, A.B., and Diehl, J.A. (2003). An alternatively spliced cyclin D1 isoform, cyclin 
D1b, is a nuclear oncogene. Cancer Res 63, 7056-7061. 
Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E., and Kutay, U. (2004). Nuclear export of 
microRNA precursors. Science 303, 95-98. 
 88
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Ma, W.J., Cheng, S., Campbell, C., Wright, A., and Furneaux, H. (1996). Cloning and 
characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 271, 
8144-8151. 
MacFarlane, M., Kohlhaas, S.L., Sutcliffe, M.J., Dyer, M.J., and Cohen, G.M. (2005). TRAIL 
receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid 
malignancies. Cancer Res 65, 11265-11270. 
Mayr, C., Hemann, M.T., and Bartel, D.P. (2007). Disrupting the pairing between let-7 and 
Hmga2 enhances oncogenic transformation. Science 315, 1576-1579. 
Mazumder, B., Seshadri, V., and Fox, P.L. (2003). Translational control by the 3'-UTR: the ends 
specify the means. Trends Biochem Sci 28, 91-98. 
Medina, R., Zaidi, S.K., Liu, C.G., Stein, J.L., van Wijnen, A.J., Croce, C.M., and Stein, G.S. 
(2008). MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. 
Cancer Res 68, 2773-2780. 
Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., and Tuschl, T. (2004). 
Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 
15, 185-197. 
Michael, M.Z., SM, O.C., van Holst Pellekaan, N.G., Young, G.P., and James, R.J. (2003). 
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1, 
882-891. 
Molenaar, J.J., van Sluis, P., Boon, K., Versteeg, R., and Caron, H.N. (2003). Rearrangements 
and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes 
Cancer 36, 242-249. 
Moss, E.G., Lee, R.C., and Ambros, V. (1997). The cold shock domain protein LIN-28 controls 
developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell 88, 637-646. 
Motokura, T., Bloom, T., Kim, H.G., Juppner, H., Ruderman, J.V., Kronenberg, H.M., and 
Arnold, A. (1991). A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 
350, 512-515. 
Motoyama, K., Inoue, H., Nakamura, Y., Uetake, H., Sugihara, K., and Mori, M. (2008). Clinical 
significance of high mobility group A2 in human gastric cancer and its relationship to let-
7 microRNA family. Clin Cancer Res 14, 2334-2340. 
 89
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Neuman, E., Ladha, M.H., Lin, N., Upton, T.M., Miller, S.J., DiRenzo, J., Pestell, R.G., Hinds, 
P.W., Dowdy, S.F., Brown, M., et al. (1997). Cyclin D1 stimulation of estrogen receptor 
transcriptional activity independent of cdk4. Mol Cell Biol 17, 5338-5347. 
O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V., and Mendell, J.T. (2005). c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 435, 839-843. 
Ota, A., Tagawa, H., Karnan, S., Tsuzuki, S., Karpas, A., Kira, S., Yoshida, Y., and Seto, M. 
(2004). Identification and characterization of a novel gene, C13orf25, as a target for 
13q31-q32 amplification in malignant lymphoma. Cancer Res 64, 3087-3095. 
Pages, G., Berra, E., Milanini, J., Levy, A.P., and Pouyssegur, J. (2000). Stress-activated protein 
kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA 
stability. J Biol Chem 275, 26484-26491. 
Pal-Bhadra, M., Bhadra, U., and Birchler, J.A. (1997). Cosuppression in Drosophila: gene 
silencing of Alcohol dehydrogenase by white-Adh transgenes is Polycomb dependent. 
Cell 90, 479-490. 
Pardee, A.B. (1974). A restriction point for control of normal animal cell proliferation. Proc Natl 
Acad Sci U S A 71, 1286-1290. 
Peppel, K., Vinci, J.M., and Baglioni, C. (1991). The AU-rich sequences in the 3' untranslated 
region mediate the increased turnover of interferon mRNA induced by glucocorticoids. J 
Exp Med 173, 349-355. 
Pesole, G., Liuni, S., Grillo, G., and Saccone, C. (1997). Structural and compositional features of 
untranslated regions of eukaryotic mRNAs. Gene 205, 95-102. 
Petersen, C.P., Bordeleau, M.E., Pelletier, J., and Sharp, P.A. (2006). Short RNAs repress 
translation after initiation in mammalian cells. Mol Cell 21, 533-542. 
Pillai, R.S., Bhattacharyya, S.N., Artus, C.G., Zoller, T., Cougot, N., Basyuk, E., Bertrand, E., 
and Filipowicz, W. (2005). Inhibition of translational initiation by Let-7 MicroRNA in 
human cells. Science 309, 1573-1576. 
Pinyol, M., Bea, S., Pla, L., Ribrag, V., Bosq, J., Rosenwald, A., Campo, E., and Jares, P. (2007). 
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA 
decay pathway inhibition and microarray analysis. Blood 109, 5422-5429. 
 90
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Qiao, D., Zeeman, A.M., Deng, W., Looijenga, L.H., and Lin, H. (2002). Molecular 
characterization of hiwi, a human member of the piwi gene family whose overexpression 
is correlated to seminomas. Oncogene 21, 3988-3999. 
Quelle, D.E., Ashmun, R.A., Shurtleff, S.A., Kato, J.Y., Bar-Sagi, D., Roussel, M.F., and Sherr, 
C.J. (1993). Overexpression of mouse D-type cyclins accelerates G1 phase in rodent 
fibroblasts. Genes Dev 7, 1559-1571. 
Quintanilla-Martinez, L., Davies-Hill, T., Fend, F., Calzada-Wack, J., Sorbara, L., Campo, E., 
Jaffe, E.S., and Raffeld, M. (2003). Sequestration of p27Kip1 protein by cyclin D1 in 
typical and blastic variants of mantle cell lymphoma (MCL): implications for 
pathogenesis. Blood 101, 3181-3187. 
Rabbitts, T.H. (1994). Chromosomal translocations in human cancer. Nature 372, 143-149. 
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, 
Z., and Oren, M. (2007). Transcriptional activation of miR-34a contributes to p53-
mediated apoptosis. Mol Cell 26, 731-743. 
Raymond, V., Atwater, J.A., and Verma, I.M. (1989). Removal of an mRNA destabilizing 
element correlates with the increased oncogenicity of proto-oncogene fos. Oncogene Res 
5, 1-12. 
Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., Horvitz, 
H.R., and Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature 403, 901-906. 
Rimokh, R., Berger, F., Bastard, C., Klein, B., French, M., Archimbaud, E., Rouault, J.P., Santa 
Lucia, B., Duret, L., Vuillaume, M., et al. (1994a). Rearrangement of CCND1 
(BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated 
leukemias. Blood 83, 3689-3696. 
Rimokh, R., Berger, F., Delsol, G., Digonnet, I., Rouault, J.P., Tigaud, J.D., Gadoux, M., 
Coiffier, B., Bryon, P.A., and Magaud, J.P. (1994b). Detection of the chromosomal 
translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 83, 
1871-1875. 
 91
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Rinaldi, A., Poretti, G., Kwee, I., Zucca, E., Catapano, C.V., Tibiletti, M.G., and Bertoni, F. 
(2007). Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in 
human mantle cell lymphoma. Leuk Lymphoma 48, 410-412. 
Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, 
R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., et al. (2003). The 
proliferation gene expression signature is a quantitative integrator of oncogenic events 
that predicts survival in mantle cell lymphoma. Cancer Cell 3, 185-197. 
Rowley, J.D. (1998). The critical role of chromosome translocations in human leukemias. Annu 
Rev Genet 32, 495-519. 
Rudelius, M., Pittaluga, S., Nishizuka, S., Pham, T.H., Fend, F., Jaffe, E.S., Quintanilla-Martinez, 
L., and Raffeld, M. (2006). Constitutive activation of Akt contributes to the pathogenesis 
and survival of mantle cell lymphoma. Blood 108, 1668-1676. 
Salaverria, I., Perez-Galan, P., Colomer, D., and Campo, E. (2006). Mantle cell lymphoma: from 
pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 
91, 11-16. 
Sandberg, R., Neilson, J.R., Sarma, A., Sharp, P.A., and Burge, C.B. (2008). Proliferating cells 
express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. 
Science 320, 1643-1647. 
Sander, B., Flygare, J., Porwit-Macdonald, A., Smith, C.I., Emanuelsson, E., Kimby, E., Liden, 
J., and Christensson, B. (2005). Mantle cell lymphomas with low levels of cyclin D1 long 
mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 
and cyclin B1. Int J Cancer 117, 418-430. 
Sarkar, B., Lu, J.Y., and Schneider, R.J. (2003). Nuclear import and export functions in the 
different isoforms of the AUF1/heterogeneous nuclear ribonucleoprotein protein family. J 
Biol Chem 278, 20700-20707. 
Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003). Asymmetry 
in the assembly of the RNAi enzyme complex. Cell 115, 199-208. 
Shaw, G., and Kamen, R. (1986). A conserved AU sequence from the 3' untranslated region of 
GM-CSF mRNA mediates selective mRNA degradation. Cell 46, 659-667. 
Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677. 
 92
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Siegert, J.L., Rushton, J.J., Sellers, W.R., Kaelin, W.G., Jr., and Robbins, P.D. (2000). Cyclin D1 
suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. 
Oncogene 19, 5703-5711. 
Solomon, D.A., Wang, Y., Fox, S.R., Lambeck, T.C., Giesting, S., Lan, Z., Senderowicz, A.M., 
Conti, C.J., and Knudsen, E.S. (2003). Cyclin D1 splice variants. Differential effects on 
localization, RB phosphorylation, and cellular transformation. J Biol Chem 278, 30339-
30347. 
Sonoki, T., Iwanaga, E., Mitsuya, H., and Asou, N. (2005). Insertion of microRNA-125b-1, a 
human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a 
patient with precursor B-cell acute lymphoblastic leukemia. Leukemia 19, 2009-2010. 
Stoecklin, G., Ming, X.F., Looser, R., and Moroni, C. (2000). Somatic mRNA turnover mutants 
implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol 
20, 3753-3763. 
Suzuki, M., Iijima, M., Nishimura, A., Tomozoe, Y., Kamei, D., and Yamada, M. (2005). Two 
separate regions essential for nuclear import of the hnRNP D nucleocytoplasmic shuttling 
sequence. FEBS J 272, 3975-3987. 
Tagawa, H., Karube, K., Tsuzuki, S., Ohshima, K., and Seto, M. (2007). Synergistic action of the 
microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 98, 
1482-1490. 
Tazawa, H., Tsuchiya, N., Izumiya, M., and Nakagama, H. (2007). Tumor-suppressive miR-34a 
induces senescence-like growth arrest through modulation of the E2F pathway in human 
colon cancer cells. Proc Natl Acad Sci U S A 104, 15472-15477. 
Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, 
F., Alder, H., Croce, C.M., et al. (2007). MicroRNAs (miR)-221 and miR-222, both 
overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels 
and cell cycle. Endocr Relat Cancer 14, 791-798. 
Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., 
Roldo, C., Ferracin, M., et al. (2006). A microRNA expression signature of human solid 
tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103, 2257-2261. 
 93
                                                                                                              R  e  f  e  r  e  n  c  e  s   
 
 
Wagner, B.J., DeMaria, C.T., Sun, Y., Wilson, G.M., and Brewer, G. (1998). Structure and 
genomic organization of the human AUF1 gene: alternative pre-mRNA splicing generates 
four protein isoforms. Genomics 48, 195-202. 
Wang, S.W., Pawlowski, J., Wathen, S.T., Kinney, S.D., Lichenstein, H.S., and Manthey, C.L. 
(1999). Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated 
protein kinase. Inflamm Res 48, 533-538. 
Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., 
Rosenwald, A., Muller-Hermelink, H.K., Ott, G., et al. (2007). Point mutations and 
genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are 
associated with increased proliferation rate and shorter survival. Blood 109, 4599-4606. 
Winzen, R., Kracht, M., Ritter, B., Wilhelm, A., Chen, C.Y., Shyu, A.B., Muller, M., Gaestel, 
M., Resch, K., and Holtmann, H. (1999). The p38 MAP kinase pathway signals for 
cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an 
AU-rich region-targeted mechanism. EMBO J 18, 4969-4980. 
Witzig, T.E., Vukov, A.M., Habermann, T.M., Geyer, S., Kurtin, P.J., Friedenberg, W.R., White, 
W.L., Chalchal, H.I., Flynn, P.J., Fitch, T.R., et al. (2005). Rituximab therapy for patients 
with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a 
phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23, 1103-1108. 
Xu, N., Chen, C.Y., and Shyu, A.B. (1997). Modulation of the fate of cytoplasmic mRNA by 
AU-rich elements: key sequence features controlling mRNA deadenylation and decay. 
Mol Cell Biol 17, 4611-4621. 
Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M.C., Liu, M., Wu, K., Whittle, J., Ju, X., Hyslop, 
T., et al. (2008). A cyclin D1/microRNA 17/20 regulatory feedback loop in control of 
breast cancer cell proliferation. J Cell Biol 182, 509-517. 
Zeng, Y., Yi, R., and Cullen, B.R. (2003). MicroRNAs and small interfering RNAs can inhibit 
mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A 100, 9779-9784. 
Zhang, J., Tsaprailis, G., and Bowden, G.T. (2008). Nucleolin stabilizes Bcl-X L messenger 
RNA in response to UVA irradiation. Cancer Res 68, 1046-1054. 
Zhao, W., Liu, M., and Kirkwood, K.L. (2008). p38alpha stabilizes interleukin-6 mRNA via 
multiple AU-rich elements. J Biol Chem 283, 1778-1785.
 94
                                                                               A  c  k  n  o  w  l  e  d  g  e  m  e  n  t  s  
 
 
 95
Acknowledgements 
 
 
 Over the years, there are a lot of people who have helped me towards the completion of 
this work. I would like to take this opportunity to express my feeling of gratitude to my family. 
My parents, who were my pillars of strength throughout the phases of my career and my parents 
in-law, Pradyumna and Rashmi who provided me with much needed moral and emotional 
support. 
I would like to thank my supervisor and thesis advisor Prof. Dr. Martin Dreyling for 
giving me the opportunity and guiding and encouraging me, without which this would not have 
been possible. Discussions with Prof. Stefan Bohlander have always been helpful in driving my 
project in a focussed direction. I gained a lot of knowledge of this subject through insightful 
conversations with him.  I would like to thank Prof. Dirk Eick for his valuable inputs in the 
project and Prof. Wolfgang Hiddemann for his support. 
 Working in research labs abroad, miles away from home was a unique experience for me. 
Marc, Grit and Yvonne were responsible for making me feel comfortable in our small working 
group. I am grateful to Alessandro who designed this project and introduced me to the working 
group. Yvonne always showed enthusiasm in helping me learn new techniques. I came to know 
what an ‘organised person’ meant when I worked with her. Marc has been extremely friendly and 
helpful at all times. He has been a very patient listener in those depressing times of no results. I 
could learn time management from Grit, who plans and completes her work in a given time 
frame. Medhanie never shied away from lending a helping hand in statistical analyses and other 
things.  My heartfelt thanks to all the members of the Clinical Cooperative Group-Leukemia and 
from the GSF for being helpful and supportive all the time. I would like to thank Bianka for her 
excellent assistance with the FACS calibur and FACS sorter.  
 For the non-scientific side of my thesis, I want to thank the Desi gang who made my stay 
in Germany memorable. My special thanks to Farid and Naidu for being very helpful in the 
institute and at home as well. I appreciate Sandhya, Mehar, and Pratibha for being good friends. 
                                                                               A  c  k  n  o  w  l  e  d  g  e  m  e  n  t  s  
 
 
It is difficult to forget those trips full of fun and joy.  I am thankful to the Rawat family, 
especially Bhabhiji for giving me that ‘homely feeling’ whenever needed. Special thanks are due, 
to my friend Purvi who supported me in all seasons. She was really patient in hearing those long 
monologues.  
A special word of mention for the children, Shivam, Aditya, and the two babies, Sarah 
and Bhargavi, who were stress relievers and it was a lot of joy watching them grow.  
I also want to thank our ‘Eliteastrites’ group members especially Bibhuti who has been a 
constant source of encouragement for me in pursuing my PhD. All the members of the group 
used to be very prompt in urgently providing me with research articles. I appreciate my old 
friends from school who cheered me up whenever I got exhausted during thesis writing. 
 Finally, I am forever indebted to my husband, Aniruddha for his understanding, endless 
patience and encouragement when it was most required. I owe him thanks for his help in setting 
up experiments and for scientific discussions throughout the PhD project. Correcting my first 
presentations, helping me make clearer ideas, Ani contributed a lot to the entire PhD work. He 
always stood by me in good and bad times. I can say that I am lucky to have such a loving soul 
mate that played both the roles of husband and a colleague successfully.  
 
 
 
 
 
 
 
 
 
 
 96
                                                                                   C  u  r  r  i  c  u  l  u  m    V  i  t  a  e 
 
Curriculum Vitae 
 
 
Anagha Deshpande 
Maiden name: Anagha Borwankar 
 
Pfingstrosenstrasse 64, Munich, 81377,  
Germany 
Tel: (49)(89) 7099425 
anaghab02@gmail.com 
 
 
EDUCATION 
 
University of Mumbai, Mumbai 
M.Tech. in Biotechnology 2004 
Dissertation: “Selective Extraction of Carotenoids from Plant Source” 
 
University of Mumbai, Mumbai 
B.Pharm. Sc. 2001 
 
Areas of Concentration: Pharmacology,Pharmaceutics, Biochemistry  
Minor: Biotechnology 
 
 
RESEARCH EXPERIENCE 
 
University Institute of Chemical Technology, Mumbai  
Master’s student – “Selective Extraction of Carotenoids from 
Plant Source” 
2003-2004 
Worked on different methods of extraction of β-carotene from plant sources and its pharmacological 
activity. 
 
Astra Zeneca Ltd, Bangalore, India  
Assistant Research Scientist – “Enzyme assay development” 2004-2005 
Worked on Enzyme kinetics involving assay development, optimization and high throughput 
screening in the field of tuberculosis. 
 
University Hospital of the Ludwigs Maximillilans University at 
Grosshadern and the Helmholtz Centre 
 
 
Doctoral student-  “Regulation of the cyclin D1 by cell cycle 
regulatory microRNAs ” 
2006-2008 
 97
                                                                                   C  u  r  r  i  c  u  l  u  m    V  i  t  a  e 
 98
 Identified the microRNAs predicted to bind to the 3’UTR of cyclin D1 experimentally and showed 
the regulatory role of the 3’UTR in cyclin D1 expression in-vitro. 
 
PRESENTATIONS 
 
IPC, Chennai 
Poster presentation – 55th Indian Pharmaceutical Congress (IPC) 
  
2003 
 
Herrsching 
Poster presentation – 8th Wissenschaftliches Symposium der 
Medizinischen Klinik III Klinikum der Universität München-
Grosshadern 
 
2006 
Herrsching 
Oral presentation –  9th Wissenschaftliches Symposium der 
Medizinischen Klinik III Klinikum der Universität München-
Grosshadern 
 
2007 
DGHO, Basel 
Poster presentation – Gemeinsame Jahrestagung der D/AT/CH 
Gesellschaften für Hämatologie und Onkologie 
 
2007 
Herrsching 
Poster presentation-10th Wissenschaftliches Symposium der 
Medizinischen Klinik III    Klinikum der Universität München-
Grosshadern 
 
2008 
DGHO, Vienna 
Oral presentation- Gemeinsame Jahrestagung der D/AT/CH 
Gesellschaften für Hämatologie und Onkologie 
 
2008 
ASH, San Francisco 
 
Poster presentation –50th Annual Scientific Meeting of the 
American Society of Hematology (ASH) 
 
2008 
 
PUBLICATIONS  
 
 Borwankar A., Pastore A.,Deshpande A.,Buske C.,Weigert O.,Dreyling M; CyclinD1 Regulation by 
MicroRNAs and Implications in Mantle Cell Lymphoma Onkologie 2007;30 (suppl 3):150 ( 
Onkologie abstracts, 2007) 
 
Borwankar A., Pastore A., Deshpande A., Zimmermann Y., Buske C., Hiddemann W., Dreyling M.; 
The Role of MicroRNAs in Mantle Cell Lymphoma Onkologie 2008;31(suppl 4):7 (Onkologie 
                                                                                   C  u  r  r  i  c  u  l  u  m    V  i  t  a  e 
 99
abstracts, 2008) 
 
Borwankar A., Pastore A., Deshpande A., Zimmermann Y., Buske C., Hiddemann W., Dreyling M.; 
Regulation of the Cyclin D1 Proto-Oncogene by Cell Cycle Regulatory MicroRNAs  Blood 
2008;112 (11) (Blood abstracts,Nov.2008) 
 
 
LANGUAGES 
 
 English – speak fluently and read/write with high proficiency 
Hindi – speak fluently and read/write with high proficiency  
Marathi – speak fluently and read/write with high proficiency  
German– working knowledge of the language 
 
 
